REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Title of Class |
Trading Symbol |
Name of Each Exchange on Which Registered | ||
* |
||||
Representing One Ordinary Share, 25p per Ordinary Share |
* | |
Ordinary Shares, 25p par value |
☐ US GAAP |
☒ as Issuedby the International Accounting Standards Board |
☐ Other |
Auditor Firm Id: | Auditor Name: | Auditor Location: |
• | references to “sterling”, “pounds”, “pence” or “£” are to the lawful currency of the United Kingdom, |
• | references to “euro” or “€” are to the lawful currency of the participating Member States in the Third Stage of the European Economic and Monetary Union of the Treaty Establishing the European Commission, and |
• | references to “US dollars”, “dollars”, “cents” or “$” are to the lawful currency of the United States |
• | references to “brl”, “R$” are to the lawful currency of Brazil. |
• | operations and prospects, |
• | growth strategy, |
• | funding needs and financing resources, |
• | expected financial position, |
• | market risk, |
• | currency risk, |
• | US federal and state spending patterns, |
• | debt levels, and |
• | general market and economic conditions. |
ITEM 1. |
IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS |
ITEM 2. |
OFFER STATISTICS AND EXPECTED TIMETABLE |
ITEM 3. |
KEY INFORMATION |
ITEM 4. |
INFORMATION ON THE COMPANY |
Year Ended December 31 |
||||||||||||||||||||||||
2021 |
2021 |
2020 |
2019 |
2018 |
2017 |
|||||||||||||||||||
$ |
£ |
£ |
£ |
£ |
£ |
|||||||||||||||||||
(In millions, except for per share amounts) |
||||||||||||||||||||||||
Consolidated Income Statement data |
||||||||||||||||||||||||
Sales |
4,628 | 3,428 | 3,397 | 3,869 | 4,129 | 4,513 | ||||||||||||||||||
Operating profit/(loss) |
247 | 183 | 411 | 275 | 553 | 451 | ||||||||||||||||||
Profit/(loss) after taxation from continuing operations |
216 | 160 | 310 | 266 | 590 | 408 | ||||||||||||||||||
Profit/(loss) for the financial year |
216 | 160 | 310 | 266 | 590 | 408 | ||||||||||||||||||
Consolidated Earnings data per share |
||||||||||||||||||||||||
Basic earnings/(loss) per equity share(1) |
28.5¢ | 21.1p | 41.0p | 34.0p | 75.6p | 49.9p | ||||||||||||||||||
Diluted earnings/(loss) per equity share(2) |
28.2¢ | 20.9p | 41.0p | 34.0p | 75.5p | 49.9p | ||||||||||||||||||
Basic earnings/(loss) from continuing operations per equity share(1) |
28.5¢ | 21.1p | 41.0p | 34.0p | 75.6p | 49.9p | ||||||||||||||||||
Diluted earnings/(loss) from continuing operations per equity share(2) |
28.2¢ | 20.9p | 41.0p | 34.0p | 75.5p | 49.9p | ||||||||||||||||||
Dividends per ordinary share |
27.7¢ | 20.5p | 19.5p | 19.5p | 18.5p | 17.0p | ||||||||||||||||||
Consolidated Balance Sheet data at period end |
||||||||||||||||||||||||
Total assets (non-current assets plus current assets) |
9,913 | 7,343 | 7,451 | 7,650 | 7,905 | 7,888 | ||||||||||||||||||
Net assets |
5,778 | 4,280 | 4,134 | 4,323 | 4,525 | 4,021 | ||||||||||||||||||
Long-term obligations(3) |
(2,002 | ) | (1,483 | ) | (1,672 | ) | (1,835 | ) | (1,246 | ) | (1,662 | ) | ||||||||||||
Capital stock |
255 | 189 | 188 | 195 | 195 | 200 | ||||||||||||||||||
Number of equity shares outstanding (millions of ordinary shares) |
757 | 757 | 753 | 782 | 781 | 802 |
(1) | Basic earnings per equity share is based on profit for the financial period and the weighted average number of ordinary shares in issue during the period. |
(2) | Diluted earnings per equity share is based on diluted earnings for the financial period and the diluted weighted average number of ordinary shares in issue during the period. Diluted earnings comprise earnings adjusted for the tax benefit on the conversion of share options by employees and the weighted average number of ordinary shares adjusted for the dilutive effect of share options. |
(3) | Long-term obligations comprise any liabilities with a maturity of more than one year, including medium and long-term borrowings, derivative financial instruments, pension obligations, long-term provisions, deferred income and tax liabilities. |
Fiscal year |
Interim |
Final |
Total |
Interim |
Final |
Total |
||||||||||||||||||
(Pence per ordinary share) |
(Cents per ordinary share) |
|||||||||||||||||||||||
2021 |
6.3 | 14.2 | 20.5 | 8.5 | 19.2 | * | 27.7 | |||||||||||||||||
2020 |
6.0 | 13.5 | 19.5 | 7.7 | 18.5 | 26.2 | ||||||||||||||||||
2019 |
6.0 | 13.5 | 19.5 | 8.0 | 16.7 | 24.7 | ||||||||||||||||||
2018 |
5.5 | 13.0 | 18.5 | 7.2 | 16.9 | 24.1 | ||||||||||||||||||
2017 |
5.0 | 12.0 | 17.0 | 6.8 | 16.2 | 23.0 |
* |
As the 2021 final dividend had not been paid by the filing date, the dividend has been translated into cents using the noon buying rate for sterling as at December 31, 2021. |
1. | We are the world’s leading learning company with a strong brand, an unmatched scope and scale; and have the deep expertise of thousands of employees who deliver high quality, trusted learning solutions every day. |
2. | We have a great foundation of established businesses that are well-managed, cash generative and underpin the company financially. |
3. | We are bringing together the multiple facets of our expertise to deliver innovative digital learning products through a more connected commercial and consumer strategy. |
• | trademarks and other rights via its brands (including corporate and business unit brands, imprints, as well as product and service brands); |
• | copyrights for its textbook and related educational content and software code; and |
• | patents and trade secrets related to the innovative methods deployed in its key technologies. |
Name power |
Country of incorporation/residence |
Percentage interest/voting | ||
Pearson Education Inc. |
United States (Delaware) | 100% | ||
Pearson Education Ltd. |
England and Wales | 100% | ||
NCS Pearson Inc. |
United States (Minnesota) | 100% |
General use of property |
Location |
Area in square feet |
||||
Office |
Iowa City, Iowa, USA | 312,760 | ||||
Warehouse/Office |
Cedar Rapids, Iowa, USA | 205,000 | ||||
Testing |
Owatonna, Minnesota, USA | 128,000 | ||||
Office/Warehouse |
Hadley, Massachusetts, USA | 85,570 |
General use of property |
Location |
Area in square feet |
||||
Warehouse |
Cranbury, New Jersey, USA* | 886,748 | ||||
Office |
Hudson, New York, USA* | 311,473 | ||||
Office |
Westminster, London, UK* | 282,923 | ||||
Office |
Hoboken, New Jersey, USA* | 216,273 | ||||
Office |
Bloomington, Minnesota, USA* | 147,159 | ||||
Warehouse/Office |
Cedar Rapids, Iowa, USA | 119,682 | ||||
Office |
San Antonio, Texas, USA* | 117,063 | ||||
Warehouse |
Naucalpan de Juarez, Mexico | 113,634 |
* | Properties have either been fully or partially sublet or are being marketed for sublet. |
ITEM 4A. |
UNRESOLVED STAFF COMMENTS |
ITEM 5. |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS |
• | Assessment & Qualifications — Pearson VUE, US School Assessment, Clinical Assessment, UK GCSE and A Levels and International academic qualifications |
• | Virtual Learning — Virtual Schools and Online Program Management. |
• | English Language Learning — Pearson Test of English, Institutional Courseware and English Online Solutions. |
• | Workforce Skills — BTEC, GED, TalentLens, Faethm, Pearson College and Apprenticeships |
• | Higher Education — US, Canadian and International Higher Education Courseware businesses. |
2021 |
2020 |
2019 |
||||||||||
£m |
£m |
£m |
||||||||||
Operating Profit |
183 | 411 | 275 | |||||||||
Add back: |
||||||||||||
Cost of major restructuring |
214 | — | 159 | |||||||||
Intangible charges |
51 | 80 | 163 | |||||||||
Other net gains and losses |
(63 | ) | (178 | ) | (16 | ) | ||||||
|
|
|
|
|
|
|||||||
Adjusted operating profit |
385 | 313 | 581 | |||||||||
|
|
|
|
|
|
Year ended December 31 |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
£m |
£m |
£m |
||||||||||
Assessment & Qualifications |
1,204 | 1,082 | 1,280 | |||||||||
Virtual Learning |
713 | 692 | 584 | |||||||||
English Language Learning |
238 | 218 | 320 | |||||||||
Workforce Skills |
172 | 163 | 185 | |||||||||
Higher Education |
849 | 956 | 1,102 | |||||||||
Strategic Review |
252 | 286 | 398 | |||||||||
|
|
|
|
|
|
|||||||
Total continuing operations |
3,428 | 3,397 | 3,869 | |||||||||
|
|
|
|
|
|
Year ended December 31 |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
£m |
£m |
£m |
||||||||||
UK |
355 | 319 | 385 | |||||||||
Europe |
249 | 216 | 244 | |||||||||
North America |
2,293 | 2,426 | 2,522 | |||||||||
Asia Pacific |
359 | 251 | 441 | |||||||||
Other countries |
172 | 185 | 277 | |||||||||
|
|
|
|
|
|
|||||||
Total continuing operations |
3,428 | 3,397 | 3,869 | |||||||||
|
|
|
|
|
|
Year ended December 31 |
||||||||
2021 |
2020 |
|||||||
£m |
£m |
|||||||
Cost of goods sold |
1,747 | 1,767 | ||||||
Operating expenses: |
||||||||
Distribution costs |
62 | 59 | ||||||
Selling, marketing and product development costs |
521 | 572 | ||||||
Administrative and other expenses |
802 | 816 | ||||||
Restructuring costs |
214 | — | ||||||
Other income |
(37 | ) | (45 | ) | ||||
|
|
|
|
|||||
Total net operating expenses |
1,562 | 1,402 | ||||||
Other net gains |
(63 | ) | (178 | ) | ||||
|
|
|
|
|||||
Total continuing operations |
3,246 | 2,991 | ||||||
|
|
|
|
all figures in £ millions |
Assessment & Qualifications |
Virtual Learning |
English Language Learning |
Workforce Skills |
Higher Education |
Businesses under Strategic Review |
Penguin Randon House |
Total |
||||||||||||||||||||||||
2021 |
||||||||||||||||||||||||||||||||
Sales |
1,204 | 713 | 238 | 172 | 849 | 252 | — | 3,428 |
||||||||||||||||||||||||
35 |
% |
21 |
% |
7 |
% |
5 |
% |
25 |
% |
7 |
% |
— |
100 |
% | ||||||||||||||||||
Operating profit /(loss) |
155 | (41 | ) | (15 | ) | (10 | ) | 8 | 86 | — | 183 |
|||||||||||||||||||||
Cost of majorrestructuring |
48 | 48 | 27 | 28 | 63 | — | — | 214 |
||||||||||||||||||||||||
Intangible charges |
13 | 25 | 3 | 7 | 2 | 1 | — | 51 |
||||||||||||||||||||||||
Other net gains and losses |
— | — | — | 2 | — | (65 | ) | — | (63 |
) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Adjusted operating profit |
216 | 32 | 15 | 27 | 73 | 22 | — | 385 |
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
2020 1 |
||||||||||||||||||||||||||||||||
Sales |
1,082 | 692 | 218 | 163 | 956 | 286 | — | 3,397 |
||||||||||||||||||||||||
33 |
% |
20 |
% |
6 |
% |
5 |
% |
28 |
% |
8 |
% |
— |
100 |
% | ||||||||||||||||||
Operating profit / (loss) |
118 | (1 | ) | (6 | ) | 18 | 90 | 11 | 181 | 411 |
||||||||||||||||||||||
Cost of major restructuring |
— | — | — | — | — | — | — | — |
||||||||||||||||||||||||
Intangible charges |
29 | 30 | 7 | 8 | 3 | 3 | — | 80 |
||||||||||||||||||||||||
Other net gains and losses |
— | — | — | — | — | 2 | (180 | ) | (178 |
) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Adjusted operating profit |
147 | 29 | 1 | 26 | 93 | 16 | 1 | 313 |
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1. | Comparative amounts have been represented to reflect the new operating segments. |
all figures in £ millions |
Assessment & Qualifications |
Virtual Learning |
English Language Learning |
Workforce Skills |
Higher Education |
Businesses under Strategic Review |
Penguin Randon House |
Total |
||||||||||||||||||||||||
2020 1 |
||||||||||||||||||||||||||||||||
Sales |
1,082 | 692 | 218 | 163 | 956 | 286 | — | 3,397 |
||||||||||||||||||||||||
33 |
% |
20 |
% |
6 |
% |
5 |
% |
28 |
% |
8 |
% |
— | 100 |
% | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Operating profit / (loss) |
118 | (1 | ) | (6 | ) | 18 | 90 | 11 | 181 | 411 |
||||||||||||||||||||||
Cost of major restructuring |
— | — | — | — | — | — | — | — |
||||||||||||||||||||||||
Intangible charges |
29 | 30 | 7 | 8 | 3 | 3 | — | 80 |
||||||||||||||||||||||||
Other net gains and losses |
— | — | — | — | — | 2 | (180 | ) | (178 |
) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Adjusted operating profit |
147 | 29 | 1 | 26 | 93 | 16 | 1 | 313 |
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
all figures in £ millions |
Assessment & Qualifications |
Virtual Learning |
English Language Learning |
Workforce Skills |
Higher Education |
Businesses under Strategic Review |
Penguin Randon House |
Total |
||||||||||||||||||||||||
2019 1 |
||||||||||||||||||||||||||||||||
Sales |
1,280 | 584 | 320 | 185 | 1,102 | 398 | — | 3,869 |
||||||||||||||||||||||||
33 |
% |
15 |
% |
8 |
% |
5 |
% |
29 |
% |
10 |
% |
— | 100 |
% | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Operating profit / (loss) |
191 | (36 | ) | (31 | ) | 15 | 66 | 19 | 51 | 275 |
||||||||||||||||||||||
Cost of major restructuring |
38 | 13 | 10 | 7 | 68 | 21 | 2 | 159 |
||||||||||||||||||||||||
Intangible charges |
23 | 36 | 80 | 9 | — | 3 | 12 | 163 |
||||||||||||||||||||||||
Other net gains and losses |
— | — | — | — | — | (16 | ) | — | (16 |
) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Adjusted operating profit |
252 | 13 | 59 | 31 | 134 | 27 | 65 | 581 |
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1. | Comparative amounts have been represented to reflect the new operating segments. |
Year ended December 31, 2021 |
||||||||||||||||||||
Total |
Less than one year |
One to Two years |
Two to five years |
After five years |
||||||||||||||||
£m |
£m |
£m |
£m |
£m |
||||||||||||||||
Gross Borrowings: |
||||||||||||||||||||
Bank loans and overdrafts |
— | — | — | — | — | |||||||||||||||
Revolving credit facility |
— | — | — | — | — | |||||||||||||||
Bonds |
767 | 87 | 70 | 257 | 353 | |||||||||||||||
Lease liabilities |
633 | 68 | 71 | 178 | 316 | |||||||||||||||
Deferred consideration |
44 | 6 | 15 | 13 | 10 | |||||||||||||||
UK pension funding obligation |
— | — | — | — | — | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total |
1,444 | 161 | 156 | 448 | 679 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
ITEM 6. DIRECTORS, |
SENIOR MANAGEMENT AND EMPLOYEES |
Name |
Age |
Position | ||||
Sidney Taurel |
73 | Chair | ||||
Andy Bird, CBE |
58 | Chief Executive | ||||
Sally Johnson |
48 | Chief Financial Officer | ||||
Sherry Coutu, CBE |
58 | Non-executive Director | ||||
Esther Lee |
63 | Non-executive Director | ||||
Linda Lorimer |
69 | Non-executive Director | ||||
Graeme Pitkethly |
55 | Non-executive Director | ||||
Tim Score |
61 | Senior Independent Director and Deputy Chair Designate | ||||
Lincoln Wallen |
61 | Non-executive Director |
Name |
Position | |
Tom ap Simon |
President, Virtual Learning | |
Ali Bebo |
Chief Human Resources Officer | |
Tim Bozik |
President, Higher Education; Interim Chief Product Officer and Co-President, Direct to Consumer | |
Lynne Frank |
Chief Marketing Officer and Co-President, Direct-to- Consumer | |
Gio Giovannelli |
President, English Language Learning | |
Mike Howells |
President, Workforce Skills | |
Cinthia Nespoli |
Chief Legal Officer | |
Art Valentine |
President, Assessment & Qualifications |
• | Determine and regularly review the remuneration policies for the Executive Directors and other members of Pearson’s Executive management (who report directly to the Chief Executive). This includes base salary, incentive arrangements, pension arrangements, any other benefits and entitlements on termination of employment. When setting remuneration policy and packages, the Committee takes into account all factors which it deems necessary, including wider remuneration practices and related policies for the wider workforce. |
• | Ensure the company maintains an appropriate level of engagement with its shareholders and shareholder representative bodies in relation to the Directors’ Remuneration Policy and its implementation. |
• | Regularly review the implementation and operation of the Directors’ Remuneration Policy and approve the individual remuneration and benefits packages of Executive management. |
• | Approve the design of, and determine targets for, any performance-related pay plans operated by the Group for Pearson Executive management and approve the total payments to be made under such plans. |
• | Advise and decide on general and specific remuneration arrangements in connection with the termination of employment of Executive management. |
• | Delegated responsibility for determining the remuneration and benefits package of the Chair of the Board. |
• | Review updates from management on talent, retention and gender pay gap. |
• | Have oversight of workforce remuneration, policies and practice for the wider organization. |
• | Where a new Executive Director has been appointed to the Board at a lower than typical market salary to allow for growth in the role then larger increases may be awarded to move salary positioning closer to typical market level as the Executive Director gains experience. |
• | Where an Executive Director has been promoted or has had a change in responsibilities. |
• | Where there has been a significant change in market practice or where there has been a significant change in the size and/or scope of the business. |
• | travel-related benefits (such as company car, car allowance and private use of a driver); |
• | health-related benefits (such as healthcare, health assessment and gym benefit); |
• | and risk benefits (such as additional life cover and long-term disability insurance that are not covered by the company’s retirement plans). |
• | Accelerating growth through digital transformation and business model innovation |
• | Establishing Pearson as purpose-driven across product, people and the planet |
Weighting |
Threshold |
Target |
Maximum | |||||
Digital sales growth |
10% | Plan less 2% | Plan | Plan plus 2% | ||||
Invest in diverse pipeline and increase representation at management levels |
5% | 50% female and ethnic minority representation in leadership development and mentoring programmes + 50% female and 20% ethnic minority representation in leadership succession plans |
Threshold + 5% increase in female and ethnic minority representation at VP level and above | Threshold + 10% increase in female and ethnic minority representation at VP level and above | ||||
Reduce carbon footprint – net annual reduction versus 2021 baseline |
5% | 1% reduction | 2% reduction | 5% reduction |
EPS (1/3) |
Net ROIC (1/3) |
Relative TSR (1/3) | ||||||||
Vesting schedule (% of max) |
Adjusted EPS for FY23 |
Vesting schedule (% of max) |
Adjusted net ROIC for FY23 |
Vesting schedule (% of max) |
Ranked position vs. FTSE 100 | |||||
15% |
46.5p | 15% | 5.5% | 25% | Median | |||||
65% |
53.5p | 65% | 6.5% | — | — | |||||
100% |
61.0p | 100% | 7.5% | 100% | Upper quartile |
Note: | straight line vesting between points shown, with no vesting for performance below threshold. |
EPS (1/3) |
Net ROIC (1/3) |
Relative TSR (1/3) | ||||||||
Vesting schedule (% of max) |
Adjusted EPS for FY23 |
Vesting schedule (% of max) |
Adjusted net ROIC for FY23 |
Vesting schedule (% of max) |
Ranked position vs. FTSE 100 | |||||
15% |
48.0p | 15% | 6.0% | 25% | Median | |||||
65% |
55.0p | 65% | 7.0% | — | — | |||||
100% |
64.0p | 100% | 8.0% | 100% | Upper quartile |
• | an appropriate level of progress being made in relation to delivering our strategy including our ongoing transition from print to digital |
• | no significant ESG issues related to Andy’s tenure occurring which result in significant reputational damage |
• | the company’s TSR from the date of the announcement of Andy’s appointment to 31 December 2023 is either (1) positive; or (2) is at median or above when compared to the performance of the FTSE 100 |
• | Awards that are subject to performance conditions will stay in force as if the participant had not ceased employment and shall vest on the original vesting date / be released in line with normal time horizons. |
• | Awards that are not subject to a performance condition will be released as soon as practicable following cessation of employment. |
• | The number of shares that are released shall be pro-rated for the period of the participant’s service in the restricted period (although the Committee may in its absolute discretion waive or vary the pro-rating). |
With effect from April 2022 |
||||
Non-Executive Director |
£ | 70,000 | ||
Chairmanship of Audit Committee |
£ | 27,500 | ||
Chairmanship of Remuneration Committee |
£ | 22,000 | ||
Chairmanship of Nomination and Governance Committee |
£ | 15,000 | ||
Chairmanship of Reputation and Responsibility Committee |
£ | 15,000 | ||
Membership of Audit Committee |
£ | 15,000 | ||
Membership of Remuneration Committee |
£ | 10,000 | ||
Membership of Nomination and Governance Committee |
£ | 8,000 | ||
Membership of Reputation and Responsibility Committee |
£ | 8,000 | ||
Senior Independent Director (until 2022 AGM) |
£ | 22,000 | ||
Deputy Chair (from 2022 AGM) |
£ | 175,000 |
(1) | The fee paid to the Chair remains unchanged for 2022 at £500,000. |
(2) | The fees paid to Non-Executive Directors are unchanged for 2022. |
(3) | Non-Executive Directors serve Pearson under letters of appointment and do not have service contracts. There is no entitlement to compensation on the termination of their directorships. |
Base Salary/ Fees |
Allowances & Benefits(1) |
Annual Incentives |
Long-term Incentives |
Co-investment plan |
Retirement Benefits |
Total |
||||||||||||||||||||||
£000 |
£000 |
£000 |
£000 |
£000 |
£000 |
£000 |
||||||||||||||||||||||
Chair |
||||||||||||||||||||||||||||
Sidney Taurel |
500 | — | — | — | — | — | 500 | |||||||||||||||||||||
Non-Executive Directors |
||||||||||||||||||||||||||||
Elizabeth Corley |
111 | — | — | — | — | — | 111 | |||||||||||||||||||||
Sherry Coutu |
92 | — | — | — | — | — | 92 | |||||||||||||||||||||
Vivienne Cox |
43 | — | — | — | — | — | 43 | |||||||||||||||||||||
Linda Lorimer |
100 | — | — | — | — | — | 100 | |||||||||||||||||||||
Michael Lynton |
31 | — | — | — | — | — | 31 | |||||||||||||||||||||
Graeme Pitkethly |
93 | — | — | — | — | — | 93 | |||||||||||||||||||||
Tim Score |
130 | — | — | — | — | — | 130 | |||||||||||||||||||||
Lincoln Wallen |
93 | — | — | — | — | — | 93 | |||||||||||||||||||||
Annette Thomas |
21 | — | — | — | — | — | 21 | |||||||||||||||||||||
Executive Directors |
||||||||||||||||||||||||||||
Andy Bird |
910 | 271 | 1,145 | — | 2,696 | 145 | 5,167 | |||||||||||||||||||||
Sally Johnson |
521 | 16 | 560 | — | — | 58 | 1,155 | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Board of Directors |
2,645 |
287 |
1,705 |
— |
2,696 |
203 |
7,536 |
|||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) | Travel benefits include car allowance and reimbursements of a taxable nature resulting from business travel and engagements. Health benefits comprise healthcare, health assessment and dental care. Risk-related benefits comprise of life and other insurance policies. Accommodation benefits for Andy Bird relate to a contribution towards the rental costs of an apartment in New York to be used for business purposes, the cost of which has been capped at $240,000 per year ($20,000 per month) prior to any taxes which may be due. In addition to the allowances and benefits set out, Executive Directors may also participate in company benefit or policy arrangements that have no taxable value and/ or are available to all other employees in the same location. Sally Johnson’s life cover is arranged under The Pearson Pension Plan’s UK group-wide policy. |
(2) | Remuneration for Andy Bird has been converted using a USD: GBP exchange rate of 1.3753 (average exchange rate for 2021). |
(3) | Elizabeth Corley stepped down from the Board on 31 December 2021. |
(4) | Vivienne Cox stepped down from the Board on 30 April 2021. |
(5) | Michael Lynton stepped down from the Board on 30 April 2021. |
(6) | Annette Thomas joined the Board on 1 October 2021. |
As at 31 December 2021 |
Ordinary Shares (1) |
Conditional Shares |
||||||
Chair |
||||||||
Sidney Taurel |
234,894 | — | ||||||
Executive Directors |
||||||||
Andy Bird |
586,437 | 1,541,177 | ||||||
Sally Johnson |
20,265 | 384,655 | ||||||
Non-Executive Directors |
||||||||
Elizabeth Corley |
39,206 | — | ||||||
Sherry Coutu |
6,566 | — | ||||||
Vivienne Cox |
9,220 | — | ||||||
Linda Lorimer |
15,435 | — | ||||||
Michael Lynton |
20,820 | — | ||||||
Graeme Pitkethly |
9,162 | — | ||||||
Tim Score |
54,593 | — | ||||||
Lincoln Wallen |
13,490 | — | ||||||
Annette Thomas |
— | — |
(1) | Share interests are shown as at 31 December 2021. For Directors who stepped down from the Board during the year, share interests are shown as at the date of their stepping down. |
(2) | Ordinary shares include both ordinary shares listed on the London Stock Exchange and American Depositary Receipts (ADRs) listed on the New York Stock Exchange. The figures include both shares and ADRs acquired by individuals under the long-term incentive plan and any other share plans they might have participated in. |
(3) | Conditional shares means unvested shares which remain subject to performance conditions, performance underpins and/or continuing employment for a pre-defined period. |
(4) | The register of Directors’ interests contains full details of Directors’ shareholdings and options to subscribe for shares. The market price on December 31, 2021 was 613.20 p per share and the range during the year was 571.80 p to 869.40 p. |
(5) | Andy Bird‘s first tranche of the Co-investment plan, 412,933 shares (including 9,980 dividend equivalent shares), vested on 25 February 2022, taking his conditional shares to 1,345,808 (after the sales of shares to cover any tax liability). The vested co-investment shares are subject to a holding period until 31 December 2023 and are subject to continued employment. There have been no other changes in the interests of any Director between 31 December 2021 and 30 March 2022, being the latest practicable date prior to the publication of this report. |
All figures in £ millions |
2021 |
|||
Short-term employee benefits |
6 | |||
Retirement benefits |
1 | |||
Share-based payment costs |
8 | |||
|
|
|||
Total |
15 |
|||
|
|
• | 20,744 in fiscal 2021, and |
• | 21,191 in fiscal 2020, and |
• | 22,243 in fiscal 2019. |
Average number employed |
2021 |
2020 |
2019 |
|||||||||
UK |
3,395 | 3,304 | 3,309 | |||||||||
Other European Countries |
878 | 886 | 927 | |||||||||
US |
11,757 | 11,432 | 12,286 | |||||||||
Canada |
593 | 648 | 694 | |||||||||
Asia Pacific |
2,738 | 2,812 | 2,800 | |||||||||
Other Countries |
1,383 | 2,109 | 2,227 | |||||||||
|
|
|
|
|
|
|||||||
Continuing operations |
20,744 |
21,191 |
22,243 |
|||||||||
|
|
|
|
|
|
ITEM 7. |
MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS |
Name of Shareholder |
Number of ordinary shares held |
% of outstanding ordinary shares represented by number of shares held* |
||||||
Cevian Capital II GP Limited Inc |
77,163,275 | 10.19 | % | |||||
Schroders plc |
75,127,663 | 9.98 | % | |||||
Silchester International Investors LLP |
75,051,050 | 9.97 | % | |||||
Blackrock, Inc |
52,766,197 | 7.00 | % | |||||
Ameriprise Financial Inc and its group |
41,236,375 | 5.02 | % | |||||
Libyan Investment Authority** |
24,431,000 | 3.01 | % |
* | % of Issued share capital on date notified |
** | Based on notification to the company dated 7 June 2010. We have been notified of no change to this holding since that date. Assets belonging to, or owned, held or controlled on 16 September 2011 by the Libyan Investment Authority and located outside Libya on that date, are frozen in accordance with The Libya (Sanctions) (EU Exit) Regulations 2020. |
ITEM 8. |
FINANCIAL INFORMATION |
ITEM 9. |
THE OFFER AND LISTING |
ITEM 10. |
ADDITIONAL INFORMATION |
(a) | any requirement as to quorum at the meeting at which the matter is considered is met without counting the Director in question or any other interested Director; and |
(b) | the matter was agreed to without their voting or would have been agreed to if their votes had not been counted. |
(a) | may be a party to, or otherwise interested in, any transaction or arrangement with the company or in which the company is otherwise (directly or indirectly) interested; |
(b) | may act by himself or herself or his or her firm in a professional capacity for the company (otherwise than as auditor) and he or she or his or her firm shall be entitled to remuneration for professional services as if he or she were not a Director; |
(c) | may be a Director or other officer of, or employed by, or a party to a transaction or arrangement with, or otherwise interested in, any body corporate in which the company is otherwise (directly or indirectly) interested. |
(a) | the acceptance, entry into or existence of which has been approved by the Board (subject, in any such case, to any limits or conditions to which such approval was subject); or |
(b) | which he or she is permitted to hold or enter into by virtue of paragraph (a), (b) or (c) above; |
(a) | to disclose any such information to the Board or to any Director or other officer or employee of the company; and/or |
(b) | to use or apply any such information in performing his or her duties as a Director of the company. |
(a) | absents himself or herself from meetings of the Board at which any matter relating to the conflict of interest or possible conflict of interest will or may be discussed or from the discussion of any such matter at a meeting or otherwise; and/or |
(b) | makes arrangements not to receive documents and information relating to any matter which gives rise to the conflict of interest or possible conflict of interest sent or supplied by the company and/or for such documents and information to be received and read by a professional adviser, for so long as he or she reasonably believes such conflict of interest or possible conflict of interest subsists. |
• | the giving of any guarantee, security or indemnity in respect of money lent or obligations incurred by him or her or by any other person at the request of or for the benefit of the company or any of its subsidiaries; |
• | the giving of any guarantee, security or indemnity to a third party in respect of a debt or obligation of the company or any of its subsidiaries for which he himself or she herself has assumed responsibility in whole or in part and whether alone or jointly with others under a guarantee or indemnity or by the giving of security; |
• | any proposal relating to the company or any of its subsidiary undertakings where it is offering securities in which offer a Director is or may be entitled to participate as a holder of securities or in the underwriting or sub-underwriting of which a Director is to participate; |
• | any proposal relating to another company in which he or she and any persons connected with him or her do not to his or her knowledge hold an interest in shares (as that term is used in sections 820 to 825 of the Act) representing one per cent or more of either any class of the equity share capital, or the voting rights, in such company; |
• | any proposal relating to an arrangement for the benefit of the employees of the company or any of its subsidiary undertakings which does not award him or her any privilege or benefit not generally awarded to the employees to whom such arrangement relates; and |
• | any proposal concerning insurance that the company proposes to maintain or purchase for the benefit of Directors or for the benefit of persons, including Directors. |
• | approval of final dividends; |
• | consideration of the company’s annual accounts together with associated reports of the Board of Directors and auditors; |
• | appointment or reappointment of Directors; |
• | appointment or reappointment of, and determination of the remuneration of, the auditors; and |
• | renewal, limitation, extension, variation or grant of any authority to the Board in relation to the allotment and repurchase of securities. |
(a) | participate in the business for which the meeting has been convened; |
(b) | hear all persons who speak at the meeting; and |
(c) | be heard by all persons present at the meeting. |
• | consolidate and divide all or any of its share capital into shares of a larger nominal amount than its existing shares; or |
• | sub-divide all of or any of its existing shares into shares of smaller nominal amounts. |
• | the chair of the meeting; |
• | at least three shareholders present in person or by proxy and entitled to vote; |
• | any shareholder or shareholders present in person or by proxy representing not less than one-tenth of the total voting rights of all shareholders having the right to vote at the meeting; or |
• | any shareholder or shareholders present in person or by proxy holding shares conferring a right to vote at the meeting being shares on which the aggregate sum paid up is equal to not less than one-tenth of the total sum paid up on all shares conferring that right. |
• | the Group will not pay dividends (or issue shares in lieu of dividends); and |
• | the Group will not register transfers of shares unless (i) the shareholder is not himself in default as regards supplying the information requested and the transfer, when presented for registration, is accompanied by a certificate from the shareholder in such form as the Board of Directors may require to the effect that after due and careful inquiry, the shareholder is satisfied that no person in default is interested in any of the ordinary shares which are being transferred; (ii) the transfer is an approved transfer, as defined in the Articles of Association; or (iii) the registration of the transfer is required by the Uncertificated Securities Regulations 2001. |
• | an individual citizen or resident of the US, or |
• | a corporation created or organized in or under the laws of the US or any of its political subdivisions, or |
• | an estate or trust the income of which is subject to US federal income taxation regardless of its source. |
• | dealers or traders in securities or currencies, |
• | financial institutions or other US holders that treat income in respect of the ordinary shares or ADSs as financial services income, |
• | insurance companies, |
• | tax-exempt entities, |
• | persons acquiring shares or ADSs in connection with employment, |
• | US holders that hold the ordinary shares or ADSs as a part of a straddle or conversion transaction or other arrangement involving more than one position, |
• | US holders that own, or are deemed for US tax purposes to own, 10% or more of the total combined voting power of all classes of the Group’s voting stock, |
• | US holders that have a principal place of business or “tax home” outside the United States, or |
• | US holders whose “functional currency” is not the US dollar. |
ITEM 11. |
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
• | To maintain a strong balance sheet and a solid investment grade credit rating; |
• | To continue to invest in the business organically and through acquisitions; and |
• | To have a sustainable and progressive dividend policy. |
• | Issuing fixed rate debt in USD; |
• | Issuing fixed debt in euro and swapping it to British Pounds Sterling (GBP) either at fixed or floating rates and swapping an element to USD either using cross currency swaps or foreign exchange swaps; |
• | Borrowing in USD at floating rates on the Group’s bank facility. |
ITEM 12. |
DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES |
Person depositing or withdrawing shares must pay to the depositary: |
For: | |
$ 5.00 (or less) per 100 ADSs (or portion of 100 ADSs) | • Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property • cancelation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates | |
$ .05 (or less) per ADS | • Any cash distribution to ADS registered holders | |
A fee equivalent to the fee that would be payable if securities distributed had been shares and the shares had been deposited for issuance of ADSs | • Distribution of securities by the depositary to ADS registered holders of deposited securities | |
$.05 (or less) per ADS per calendar year | • Depositary services | |
Registration of transfer fees | • Transfer and registration of shares on the share register to or from the name of the depositary or its agent when shares are deposited or withdrawn | |
Expenses of the depositary | • Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement) • Converting foreign currency to US dollars | |
Taxes and other governmental charges the depositary or the custodian have to pay on any ADS or share underlying an ADS, for example, stock transfer taxes, stamp duty or withholding taxes | • As necessary | |
Any charges incurred by the depositary or its agents for servicing the deposited securities | • As necessary |
ITEM 13. |
DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES |
ITEM 14. |
MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS |
ITEM 15. |
CONTROLS AND PROCEDURES |
ITEM 16A. |
AUDIT COMMITTEE FINANCIAL EXPERT |
ITEM 16B. |
CODE OF ETHICS |
ITEM 16C. |
PRINCIPAL ACCOUNTANT FEES AND SERVICES |
Auditors’ Remuneration |
2021 |
2020 |
||||||
£m |
£m |
|||||||
Audit fees |
7 | 7 | ||||||
Tax fees |
— | — | ||||||
Audit-related fees |
— | — | ||||||
All other fees |
— | — |
ITEM 16D. |
EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES |
ITEM 16E. |
PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASES |
Period |
Total number of shares purchased |
Average price paid per share |
Total number of units purchased as part of publicly announced plans or programs |
Approximate maximum value of shares that may yet be purchased under the plans or programs |
||||||||||||
February 1, 2019 – February 28, 2019 |
1,500,000 | £ | 8.97 | n/a | n/a | |||||||||||
March 1, 2019 – March 31, 2019 |
3,000,000 | £ | 8.74 | n/a | n/a | |||||||||||
October 1, 2019 – October 31, 2019 |
1,600,000 | £ | 7.39 | n/a | n/a | |||||||||||
January 1, 2020 – January 31, 2020 |
6,680,158 | £ | 5.80 | 6,680,158 | £ | 310m | ||||||||||
February 1, 2020 – February 29, 2020 |
9,958,033 | £ | 5.72 | 9,958,033 | £ | 253m | ||||||||||
March 1, 2020 – March 31, 2020 |
13,239,085 | £ | 5.28 | 13,239,085 | n/a | |||||||||||
July 1, 2020 – July 31, 2020 |
1,105,402 | £ | 5.30 | n/a | n/a | |||||||||||
March 1, 2021 – March 31, 2021 |
795,784 | £ | 8.17 | n/a | n/a | |||||||||||
September 1, 2021 – September 30, 2021 |
1,355,110 | £ | 7.38 | n/a | n/a |
ITEM 16F. |
CHANGE IN REGISTRANT ’ S CERTIFYING ACCOUNTANT |
ITEM 16G. |
CORPORATE GOVERNANCE |
ITEM 16H. |
MINE SAFETY DISCLOSURE |
ITEM 16I. |
DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS |
ITEM 17. |
FINANCIAL STATEMENTS |
ITEM 18. |
FINANCIAL STATEMENTS |
j |
Incorporated by reference from the Form 20-F of Pearson plc for the year ended December 31, 2012 and filed March 22, 2013 |
q |
Incorporated by reference from the Form 20-F of Pearson plc for the year ended December 31, 2013 and filed March 27, 2014. |
∞ | Incorporated by reference from the Form 20-F of Pearson plc for the year ended December 31, 2014 and filed March 26, 2015. |
l |
Incorporated by reference from the Form 20-F of Pearson plc for the year ended December 31, 2015 and filed March 23, 2016. |
ß | Incorporated by reference from the Form 20-F of Pearson plc for the year ended December 31, 2019 and filed April 1, 2020. |
h |
Incorporated by reference from the Form 20-F of Pearson plc for the year ended December 31, 2020 and filed April 1, 2021. |
F-2 | ||||
F-7 |
||||
F-8 |
||||
F-9 |
||||
F-11 |
||||
F-13 |
||||
F-14 |
— | testing management’s CGU reassessment and the related reallocation of goodwill, including evaluating the relative value methodology applied by management to reallocate goodwill, testing the mathematical accuracy of the allocation exercise and assessing whether goodwill is monitored or measured at a level lower than management’s revised CGUs (or aggregated CGUs); |
— | testing the mathematical integrity of management’s value in use impairment model; |
— | comparing the carrying amounts of net assets subject to impairment testing to the underlying accounting records; |
— | comparing the forecast cash flows (which include forecast sales and operating profit) to board approved budgets and strategic plans and assessing how these budgets and strategic plans are compiled, including an assessment of the historical accuracy of management’s budgeting and forecasting compared to actual results; |
— | evaluating management’s related judgments and estimates, including forecast sales growth rates and operating profit projections; |
— | comparing management’s forecasts and key assumptions to industry projections and to comparable companies where this information was available for specific CGUs (or aggregated CGUs); |
— | using professionals with specialized skill and knowledge to assist in evaluating the appropriateness of the perpetuity growth rate and discount rate for each CGU (or aggregated CGU); and |
— | comparing management’s value in use valuations (i) for businesses under strategic review with initial third party bids received after year-end less estimated disposal costs and (ii) for the remaining CGUs with valuations implied by trading and transaction multiples of the Group’s competitors where this information was available. |
— | assessing management’s right-of-use |
— | testing the mathematical accuracy of management’s right-of-use |
— | comparing the carrying amounts of the net assets subject to impairment assessment to the underlying accounting records; |
— | evaluating management’s related judgments and estimates, including the amount of achievable rent, lease start dates and lease incentives such as rent free periods; |
— | using professionals with specialized skill and knowledge to assist in evaluating the appropriateness of the assumptions used by management, including the discount rates applied; and |
— | evaluating management’s impairment trigger assessment for the Group’s remaining property portfolio not subject to impairment in 2021. |
— | understanding and evaluating management’s rationale for changing methodology for new contracts in 2021; |
— | evaluating how similar groups of contracts have been identified; |
— | testing management’s historical cost profile calculations by contract grouping; |
— | testing management’s assessment of the difference between the previous approach of determining percentage of completion by individual contract analysis and the grouping of similar contracts applied to new contracts in 2021; |
— | assessing the appropriateness of a contract grouping approach under IFRS 15; |
— | testing costs incurred to date and management’s estimates of forecast costs and revenues by reference to historical experience and current contract status; |
— | recalculating management’s percentage of cost estimates; and |
— | performing look-back tests to assess management’s historical accuracy of forecasting for contract costs. |
All figures in £ millions |
Notes |
2021 |
2020 |
2019 |
||||||||||||
Continuing operations |
||||||||||||||||
Sales |
2,3 | |||||||||||||||
Cost of goods sold |
4 | ( |
) |
( |
) | ( |
) | |||||||||
|
|
|
|
|
|
|||||||||||
Gross profit |
||||||||||||||||
Operating expenses |
4 | ( |
) |
( |
) | ( |
) | |||||||||
Other net gains and losses |
4 | |||||||||||||||
Share of results of joint ventures and associates |
12 | |||||||||||||||
|
|
|
|
|
|
|||||||||||
Operating profit |
2 | |||||||||||||||
Finance costs |
6 | ( |
) |
( |
) | ( |
) | |||||||||
Finance income |
6 | |||||||||||||||
|
|
|
|
|
|
|||||||||||
Profit before tax |
||||||||||||||||
Income tax |
7 | ( |
) | |||||||||||||
|
|
|
|
|
|
|||||||||||
Profit for the year |
||||||||||||||||
|
|
|
|
|
|
|||||||||||
Attributable to: |
||||||||||||||||
Equity holders of the company |
||||||||||||||||
Non-controlling interest |
— | |||||||||||||||
|
|
|
|
|
|
|||||||||||
Earnings per share attributable to equity holders of the company during the year |
||||||||||||||||
– basic |
8 | p |
p | 0p | ||||||||||||
– diluted |
8 | p |
p | p | ||||||||||||
|
|
|
|
|
|
All figures in £ millions |
Notes | 2021 |
2020 | 2019 | ||||||||||||
Profit for the year |
||||||||||||||||
Items that may be reclassified to the income statement |
||||||||||||||||
Net exchange differences on translation of foreign operations – Group |
( |
) |
( |
) | ( |
) | ||||||||||
Net exchange differences on translation of foreign operations – associates |
— |
— | ( |
) | ||||||||||||
Currency translation adjustment disposed |
( |
) | ||||||||||||||
Attributable tax |
7 | ( |
) | |||||||||||||
Items that are not reclassified to the income statement |
||||||||||||||||
Fair value gain on other financial assets |
||||||||||||||||
Attributable tax |
7 | ( |
) |
( |
) | ( |
) | |||||||||
Remeasurement of retirement benefit obligations – Group |
25 | ( |
) | ( |
) | |||||||||||
Remeasurement of retirement benefit obligations – associates |
— | — | ( |
) | ||||||||||||
Attributable tax |
7 | ( |
) |
|||||||||||||
|
|
|
|
|
|
|||||||||||
Other comprehensive income/(expense) for the year |
29 | ( |
) | ( |
) | |||||||||||
|
|
|
|
|
|
|||||||||||
Total comprehensive income for the year |
||||||||||||||||
|
|
|
|
|
|
|||||||||||
Attributable to: |
||||||||||||||||
Equity holders of the company |
||||||||||||||||
Non-controlling interest |
— | |||||||||||||||
|
|
|
|
|
|
All figures in £ millions |
Notes | 2021 |
2020 | |||||||||
Assets |
||||||||||||
Non-current assets |
||||||||||||
Property, plant and equipment |
10 | |||||||||||
Intangible assets |
11 | |||||||||||
Investments in joint ventures and associates |
12 | |||||||||||
Deferred income tax assets |
13 | |||||||||||
Financial assets – derivative financial instruments |
16 | |||||||||||
Retirement benefit assets |
25 | |||||||||||
Other financial assets |
15 | |||||||||||
Income tax assets |
— | |||||||||||
Trade and other receivables |
22 | |||||||||||
|
|
|
|
|||||||||
Current assets |
||||||||||||
Intangible assets – product development |
20 | |||||||||||
Inventories |
21 | |||||||||||
Trade and other receivables |
22 | |||||||||||
Financial assets – derivative financial instruments |
16 | |||||||||||
Income tax assets |
— | |||||||||||
Cash and cash equivalents (excluding overdrafts) |
17 | |||||||||||
|
|
|
|
|||||||||
Assets classified as held for sale |
32 | |||||||||||
|
|
|
|
|||||||||
Total assets |
||||||||||||
|
|
|
|
|||||||||
Liabilities |
||||||||||||
Non-current liabilities |
||||||||||||
Financial liabilities – borrowings |
18 | ( |
) |
( |
) | |||||||
Financial liabilities – derivative financial instruments |
16 | ( |
) |
( |
) | |||||||
Deferred income tax liabilities |
13 | ( |
) |
( |
) | |||||||
Retirement benefit obligations |
25 | ( |
) |
( |
) | |||||||
Provisions for other liabilities and charges |
23 | ( |
) |
( |
) | |||||||
Other liabilities |
24 | ( |
) |
( |
) | |||||||
|
|
|
|
|||||||||
( |
) |
( |
) | |||||||||
|
|
|
|
All figures in £ millions |
Notes | 2021 |
2020 | |||||||||
Current liabilities |
||||||||||||
Trade and other liabilities |
24 | ( |
) |
( |
) | |||||||
Financial liabilities – borrowings |
18 | ( |
) |
( |
) | |||||||
Financial liabilities – derivative financial instruments |
16 | ( |
) |
( |
) | |||||||
Income tax liabilities |
( |
) |
( |
) | ||||||||
Provisions for other liabilities and charges |
23 | ( |
) |
( |
) | |||||||
|
|
|
|
|||||||||
( |
) |
( |
) | |||||||||
Liabilities classified as held for sale |
32 | ( |
) | |||||||||
|
|
|
|
|||||||||
Total liabilities |
( |
) |
( |
) | ||||||||
|
|
|
|
|||||||||
Net assets |
||||||||||||
|
|
|
|
|||||||||
Equity |
||||||||||||
Share capital |
27 | |||||||||||
Share premium |
27 | |||||||||||
Treasury shares |
28 | ( |
) |
( |
) | |||||||
Capital redemption reserve |
||||||||||||
Fair value reserve |
||||||||||||
Translation reserve |
||||||||||||
Retained earnings |
||||||||||||
|
|
|
|
|||||||||
Total equity attributable to equity holders of the company |
||||||||||||
Non-controlling interest |
||||||||||||
|
|
|
|
|||||||||
Total equity |
||||||||||||
|
|
|
|
Equity attributable to equity holders of the company |
||||||||||||||||||||||||||||||||||||||||
All figures in £ millions |
Share capital |
Share premium |
Treasury shares |
Capital redemption reserve |
Fair value reserve |
Translation reserve |
Retained earnings |
Total |
Non- controlling interest |
Total equity |
||||||||||||||||||||||||||||||
At 1 January 2021 |
( |
) |
||||||||||||||||||||||||||||||||||||||
Profit for the year |
— |
— |
— |
— |
— |
— |
||||||||||||||||||||||||||||||||||
Other comprehensive income/(expense) |
— |
— |
— |
— |
( |
) |
— |
|||||||||||||||||||||||||||||||||
Total comprehensive income/(expense) |
— |
— |
— |
— |
( |
) |
||||||||||||||||||||||||||||||||||
Equity-settled transactions |
— |
— |
— |
— |
— |
— |
— |
|||||||||||||||||||||||||||||||||
Issue of ordinary shares under share option schemes |
( |
) |
— |
— |
— |
— |
— |
|||||||||||||||||||||||||||||||||
Buyback of equity |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
||||||||||||||||||||||||||||||
Purchase of treasury shares |
— |
— |
( |
) |
— |
— |
— |
— |
( |
) |
— |
( |
) | |||||||||||||||||||||||||||
Release of treasury shares |
— |
— |
— |
— |
— |
( |
) |
— |
— |
— |
||||||||||||||||||||||||||||||
Transfer of gain on disposal of FVOCI investment |
— |
— |
— |
— |
( |
) |
— |
— |
— |
— |
||||||||||||||||||||||||||||||
Dividends |
— |
— |
— |
— |
— |
— |
( |
) |
( |
) |
— |
( |
) | |||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
At 31 December 2021 |
( |
) |
||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Equity attributable to equity holders of the company | ||||||||||||||||||||||||||||||||||||||||
All figures in £ millions |
Share capital |
Share premium |
Treasury shares |
Capital redemption reserve |
Fair value reserve |
Translation reserve |
Retained earnings |
Total | Non- controlling interest |
Total equity |
||||||||||||||||||||||||||||||
At 1 January 2020 |
( |
) | ||||||||||||||||||||||||||||||||||||||
Profit for the year |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
Other comprehensive income/(expense) |
— | — | — | — | ( |
) | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||||||||||||
Total comprehensive income/(expense) |
— | — | — | — | ( |
) | — | |||||||||||||||||||||||||||||||||
Equity-settled transactions |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
Issue of ordinary shares under share option schemes |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
Buyback of equity |
( |
) | — | — | — | — | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||||||||||||
Purchase of treasury shares |
— | — | ( |
) | — | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||||
Release of treasury shares |
— | — | — | — | — | ( |
) | — | — | — | ||||||||||||||||||||||||||||||
Dividends |
— | — | — | — | — | — | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
At 31 December 2020 |
( |
) | ||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity attributable to equity holders of the company |
||||||||||||||||||||||||||||||||||||||||
All figures In £ millions |
Share capital |
Share premium |
Treasury shares |
Capital redemption reserve |
Fair value reserve |
Translation reserve |
Retained earnings |
Total |
Non- controlling interest |
Total equity |
||||||||||||||||||||||||||||||
At 1 January 2019 |
( |
) | ||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Adjustment on initial application of IFRS 16 net of tax (see note 1b) |
— | — | — | — | — | — | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||||||||||||
Adjustment on initial application of IFRIC 23 net of tax (see note 1c) |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
At 1 January 2019 (restated) |
( |
) | ||||||||||||||||||||||||||||||||||||||
Profit for the year |
— | — | — | — | — | — | ||||||||||||||||||||||||||||||||||
Other comprehensive income/(expense) |
— | — | — | — | ( |
) | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||||||||||||
Total comprehensive income/ (expense) |
— | — | — | — | ( |
) | ||||||||||||||||||||||||||||||||||
Equity-settled transactions |
— | — | — | — | — | — | ||||||||||||||||||||||||||||||||||
Tax on equity-settled transactions |
— | — | — | — | — | — | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||||||||||||
Issue of ordinary shares under share option schemes |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
Buyback of equity |
— | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||
Purchase of treasury shares |
— | — | ( |
) | — | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||||
Release of treasury shares |
— | — | — | — | — | ( |
) | — | — | — | ||||||||||||||||||||||||||||||
Transfer of gain on disposal of FVOCI investment |
— | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||
Dividends |
— | — | — | — | — | — | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
At 31 December 2019 |
( |
) | ||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All figures in £ millions |
Notes | 2021 |
2020 | 2019 | ||||||||||||
Cash flows from operating activities |
||||||||||||||||
Net cash generated from operations |
33 | |||||||||||||||
Interest paid |
( |
) |
( |
) | ( |
) | ||||||||||
Tax (paid)/received |
( |
) |
( |
) | ||||||||||||
|
|
|
|
|
|
|||||||||||
Net cash generated from operating activities |
||||||||||||||||
Cash flows from investing activities |
||||||||||||||||
Acquisition of subsidiaries, net of cash acquired |
30 | ( |
) |
( |
) | ( |
) | |||||||||
Acquisition of associates |
12 | ( |
) |
— | — | |||||||||||
Additional capital invested in associates |
— |
— | ( |
) | ||||||||||||
Purchase of investments |
( |
) |
( |
) | ( |
) | ||||||||||
Purchase of property, plant and equipment |
( |
) |
( |
) | ( |
) | ||||||||||
Purchase of intangible assets |
( |
) |
( |
) | ( |
) | ||||||||||
Disposal of subsidiaries, net of cash disposed |
31 | ( |
) | |||||||||||||
Proceeds from sale of joint ventures and associates |
31 | — |
— | |||||||||||||
Proceeds from sale of investments |
— | |||||||||||||||
Proceeds from sale of property, plant and equipment |
— | — | ||||||||||||||
Lease receivables repaid including disposals |
||||||||||||||||
Loans repaid by/(advanced to) related parties |
— |
( |
) | |||||||||||||
Interest received |
||||||||||||||||
Investment income |
— |
— | ||||||||||||||
Dividends from joint ventures and associates |
— |
|||||||||||||||
|
|
|
|
|
|
|||||||||||
Net cash (used in)/generated from investing activities |
( |
) |
( |
) | ||||||||||||
Cash flows from financing activities |
||||||||||||||||
Proceeds from issue of ordinary shares |
27 | |||||||||||||||
Buyback of equity |
27 | — |
( |
) | — | |||||||||||
Purchase of treasury shares |
28 | ( |
) |
( |
) | ( |
) | |||||||||
Proceeds from borrowings |
— |
|||||||||||||||
Repayment of borrowings |
( |
) |
( |
) | ( |
) | ||||||||||
Repayment of lease liabilities |
( |
) |
( |
) | ( |
) | ||||||||||
Dividends paid to company’s shareholders |
9 | ( |
) |
( |
) | ( |
) | |||||||||
Dividends paid to non-controlling interest |
— |
( |
) | ( |
) | |||||||||||
|
|
|
|
|
|
|||||||||||
Net cash used in financing activities |
( |
) |
( |
) | ( |
) | ||||||||||
Effects of exchange rate changes on cash and cash equivalents |
( |
) |
( |
) | ( |
) | ||||||||||
|
|
|
|
|
|
|||||||||||
Net (decrease)/increase in cash and cash equivalents |
( |
) |
( |
) | ||||||||||||
Cash and cash equivalents at beginning of year |
||||||||||||||||
|
|
|
|
|
|
|||||||||||
Cash and cash equivalents at end of year |
17 | |||||||||||||||
|
|
|
|
|
|
• | IFRS 17 ‘Insurance contracts’; |
• | Amendments to IFRS 3 ’Reference to the conceptual framework’; |
• | Amendments to IAS 1 ‘Disclosure of accounting policies’; |
• | Amendments to IAS 1 ‘Classification of liabilities as current or non-current’; |
• | Amendments to IAS 8 ‘Definition of accounting estimates’; |
• | Amendments to IAS 12 ‘Deferred tax related to assets and liabilities arising from a single transaction’; |
• | Amendments to IAS 16 ‘Proceeds before intended use’; |
• | Amendments to IAS 37 ‘Onerous contracts - costs of fulfilling a contract’; and |
• | Annual improvements to IFRS 2018-2020. |
• | Intangible assets: Goodwill |
• | Taxation |
• | Revenue: Provisions for returns |
• | Employee benefits: Pensions |
• | Property, plant and equipment: Right-of-use |
• | The application of tax legislation in relation to provisions for uncertain tax positions (see notes 7 and 34). |
• | The allocation of goodwill to the cash-generating units and groups of cash-generating units (see note 11). |
• | Whether the Group will be eligible to receive the surplus associated with the UK Group Pension Plan in recognising a pension asset (see note 25). |
• | The recoverability of goodwill balances. Key assumptions used in goodwill impairment testing are discount rates, perpetuity growth rates, forecast sales growth rates and forecast operating profits. See note 11 for further details. |
• | The level of provisions required in relation to uncertain tax positions is complex and each matter is separately assessed. The estimation of future settlement amounts is based on a number of factors including the status of the unresolved matter, clarity of legislation, range of possible outcomes and the statute of limitations. See notes 7 and 34 for further details. |
• | The level of provisions required for anticipated returns is estimated based on historical experience, customer buying patterns and retailer behaviours including stock levels. See note 3 for further details. |
• | The determination of the pension cost and defined benefit obligation of the Group’s defined benefit pension schemes depends on the selection of certain assumptions, which include the discount rate, inflation rate, salary growth and longevity. See note 25 for further details. |
• | The recoverability of right-of-use |
• | Recoverable value of right-of-use |
• | Financial instruments in particular counterparty risk and hedge effectiveness; |
• | Working capital provisions including expected credit losses on trade and other debtors and inventory obsolescence; and |
• | The assessment of the useful economic lives of product development assets. |
a. | Assets and liabilities are translated at the closing rate at the date of the balance sheet |
b. | Income and expenses are translated at average exchange rates |
c. | All resulting exchange differences are recognised as a separate component of equity. |
Buildings (freehold): |
||
Buildings (leasehold): |
||
Plant and equipment: |
Typical reason for designation |
Reporting of gains and losses on effective portion of the hedge |
Reporting of gains and losses on disposal | ||
Net investment hedge | ||||
The derivative creates a foreign currency liability which is used to hedge changes in the value of a subsidiary which transacts in that currency. | Recognised in other comprehensive income. | On the disposal of foreign operations or subsidiaries, the accumulated value of gains and losses reported in other comprehensive income is transferred to the income statement. | ||
Fair value hedges | ||||
The derivative transforms the interest profile on debt from fixed |
Gains and losses on the derivative are reported in finance income or finance costs However, an equal and opposite change is made to the carrying value of the debt (a ‘fair value adjustment’) with the benefit/cost reported in finance income or finance costs. The net result should be a zero charge on a perfectly effective hedge. | If the debt and derivative are disposed of, the value of the derivative and the debt (including the fair value adjustment) are reset to zero. Any resultant gain or loss is recognised in finance income or finance costs. | ||
Non-hedge accounted contracts | ||||
These are not designated as hedging instruments. Typically, these are short-term contracts to convert debt back to fixed rates or foreign exchange contracts where a natural offset exists. | Recognised in the income statement. No hedge accounting applies. |
• | The physical and transition risks associated with climate change; and |
• | The actions the Group is taking to meet its carbon reduction and net zero targets. |
• |
The impact on the Group’s future cash flows, and the resulting impact that such adjustments to our future cash flows would have on the outcome of the annual impairment testing of our goodwill balances (see note 11 for further details), the recognition of deferred tax assets and our assessment of going concern; |
• |
The carrying value of the Group’s assets, in particular the recoverable amounts of inventories, product development assets, intangible assets and property, plant and equipment; and |
• |
Any changes to our estimates of the useful economic lives of product development assets, intangible assets and property, plant and equipment. |
• | Assessment & Qualification – Pearson VUE, US Student Assessment, Clinical Assessment, UK GCSE and A Levels and International academic qualifications. |
• | Virtual Learning – Virtual Schools and Online Program Management. |
• | English Language Learning – Pearson T est of English, Institut ional Courseware and English Online Solutions. |
• | Higher Education – US, Canadian and International Higher Education Courseware businesses. |
• | Workforce Skills – BTEC, GED, TalentLens, Faethm, Pearson College and Apprenticeships. |
2021 |
||||||||||||||||||||||||||||||||||||
All figures in £ millions |
Notes |
Assessment & Qualifications |
Virtual Learning |
English Language Learning |
Workforce Skills |
Higher Education |
Strategic Review |
Penguin Random House |
Group |
|||||||||||||||||||||||||||
Sales |
3 | — |
||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Adjusted operating profit |
— |
|||||||||||||||||||||||||||||||||||
Cost of major restructuring |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
— |
— |
( |
) | ||||||||||||||||||||||
Intangible charges |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
— |
( |
) | |||||||||||||||||||||
Other net gains and losses |
— |
— |
— |
( |
) |
— |
— |
|||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Operating profit/(loss) |
( |
) |
( |
) |
( |
) |
— |
|||||||||||||||||||||||||||||
Finance costs |
6 | ( |
) | |||||||||||||||||||||||||||||||||
Finance income |
6 | |||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||
Profit before tax |
||||||||||||||||||||||||||||||||||||
Income tax |
7 | |||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||
Profit for the year |
||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||
Other segment items |
||||||||||||||||||||||||||||||||||||
Share of results of joint ventures and associates |
12 | — |
( |
) |
( |
) |
— |
— |
— |
|||||||||||||||||||||||||||
Depreciation and impairment |
10 | — |
||||||||||||||||||||||||||||||||||
Amortisation and impairment |
11, 20 | — |
2020 |
||||||||||||||||||||||||||||||||||||
All figures in £ millions |
Notes |
Assessment & Qualifications |
Virtual Learning |
English Language Learning |
Workforce Skills |
Higher Education |
Strategic Review |
Penguin Random House |
Group |
|||||||||||||||||||||||||||
Sales |
3 | — | ||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Adjusted operating profit |
||||||||||||||||||||||||||||||||||||
Cost of major restructuring |
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||
Intangible charges |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||||||
Other net gains and losses |
— | — | — | — | — | ( |
) | |||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Operating profit/(loss) |
( |
) | ( |
) | ||||||||||||||||||||||||||||||||
Finance costs |
6 | ( |
) | |||||||||||||||||||||||||||||||||
Finance income |
6 | |||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||
Profit before tax |
||||||||||||||||||||||||||||||||||||
Income tax |
7 | ( |
) | |||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||
Profit for the year |
||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||
Other segment items |
||||||||||||||||||||||||||||||||||||
Share of results of joint ventures and associates |
12 | — | — | — | — | — | ||||||||||||||||||||||||||||||
Depreciation and impairment |
10 | — | ||||||||||||||||||||||||||||||||||
Amortisation and impairment |
11, 20 | — |
2019 |
||||||||||||||||||||||||||||||||||||
All figures in £ millions |
Notes |
Assessment & Qualifications |
Virtual Learning |
English Language Learning |
Workforce Skills |
Higher Education |
Strategic Review |
Penguin Random House |
Group |
|||||||||||||||||||||||||||
Sales |
3 |
— |
||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Adjusted operating profit |
||||||||||||||||||||||||||||||||||||
Costs of major restructuring |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||
Intangible charges |
( |
) |
( |
) |
( |
) |
( |
) |
— |
( |
) |
( |
) |
( |
) | |||||||||||||||||||||
Other net gains and losses |
— |
— |
— |
— |
— |
— |
||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Operating profit / (loss) |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||
Finance costs |
6 |
( |
) | |||||||||||||||||||||||||||||||||
Finance income |
6 |
|||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||
Profit before tax |
||||||||||||||||||||||||||||||||||||
Income tax |
7 |
|||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||
Profit for the year |
||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||
Share of results of joint ventures and associates |
— |
— |
— |
— |
— |
|||||||||||||||||||||||||||||||
Depreciation and impairment |
— |
|||||||||||||||||||||||||||||||||||
Amortisation and impairment |
— |
Sales | Non-current assets |
|||||||||||||||||||
All figures in £ millions |
2021 |
2020 | 2019 | 2021 |
2020 | |||||||||||||||
UK |
||||||||||||||||||||
Other European countries |
||||||||||||||||||||
US |
||||||||||||||||||||
Canada |
||||||||||||||||||||
Asia Pacific |
||||||||||||||||||||
Other countries |
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total |
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
2021 |
||||||||||||||||||||||||||||
All figures in £ millions |
Assessment & Qualifications |
Virtual Learning |
English Language Learning |
Workforce Skills |
Higher Education |
Strategic Review |
Total |
|||||||||||||||||||||
Courseware |
||||||||||||||||||||||||||||
Products transferred at a point in time |
— |
— |
||||||||||||||||||||||||||
Products and services transferred over time |
— |
— |
||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
— |
— |
|||||||||||||||||||||||||||
Assessments |
||||||||||||||||||||||||||||
Products transferred at a point in time |
— |
— |
— |
|||||||||||||||||||||||||
Products and services transferred over time |
— |
— |
— |
|||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
— |
— |
— |
||||||||||||||||||||||||||
Services |
||||||||||||||||||||||||||||
Products transferred at a point in time |
— |
— |
— |
— |
||||||||||||||||||||||||
Products and services transferred over time |
— |
|||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
— |
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Total |
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020 |
||||||||||||||||||||||||||||
All figures in £ millions |
Assessment & Qualifications |
Virtual Learning |
English Language Learning |
Workforce Skills |
Higher Education |
Strategic Review |
Total |
|||||||||||||||||||||
Courseware |
||||||||||||||||||||||||||||
Products transferred at a point in time |
— |
— |
||||||||||||||||||||||||||
Products and services transferred over time |
— |
— |
||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
— |
— |
|||||||||||||||||||||||||||
Assessments |
||||||||||||||||||||||||||||
Products transferred at a point in time |
— |
— |
— |
|||||||||||||||||||||||||
Products and services transferred over time |
— |
— |
— |
|||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
— |
— |
— |
||||||||||||||||||||||||||
Services |
||||||||||||||||||||||||||||
Products transferred at a point in time |
— |
— |
— |
— |
||||||||||||||||||||||||
Products and services transferred over time |
— |
|||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
— |
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Total |
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2019 |
||||||||||||||||||||||||||||
All figures in £ millions |
Assessment & Qualifications |
Virtual Learning |
English Language Learning |
Workforce Skills |
Higher Education |
Strategic Review |
Total |
|||||||||||||||||||||
Courseware |
||||||||||||||||||||||||||||
Products transferred at a point in time |
— |
— |
||||||||||||||||||||||||||
Products and services transferred over time |
— |
— |
||||||||||||||||||||||||||
— |
— |
|||||||||||||||||||||||||||
Assessments |
||||||||||||||||||||||||||||
Products transferred at a point in time |
— |
— |
— |
|||||||||||||||||||||||||
Products and services transferred over time |
— |
— |
— |
|||||||||||||||||||||||||
— |
— |
— |
||||||||||||||||||||||||||
Services |
||||||||||||||||||||||||||||
Products transferred at a point in time |
— |
— |
— |
— |
||||||||||||||||||||||||
Products and services transferred over time |
— |
|||||||||||||||||||||||||||
— |
||||||||||||||||||||||||||||
Total |
||||||||||||||||||||||||||||
2021 |
||||||||||||||||||||||||||||
All figures in £ millions |
Sales |
Deferred income |
Committed sales |
Total remaining transaction price |
2022 |
2023 |
2024 and later |
|||||||||||||||||||||
Courseware |
||||||||||||||||||||||||||||
Products transferred at a point in time |
— |
— |
— |
|||||||||||||||||||||||||
Products and services transferred over time |
||||||||||||||||||||||||||||
Assessments |
||||||||||||||||||||||||||||
Products transferred at a point in time |
— |
— |
— |
|||||||||||||||||||||||||
Products and services transferred over time |
||||||||||||||||||||||||||||
Services |
||||||||||||||||||||||||||||
Products transferred at a point in time |
— |
— |
— |
— |
||||||||||||||||||||||||
Products and services transferred over time – subscriptions |
— |
— |
||||||||||||||||||||||||||
Products and services transferred over time – other ongoing performance obligations |
— |
— |
||||||||||||||||||||||||||
Total |
||||||||||||||||||||||||||||
2020 | ||||||||||||||||||||||||||||
All figures in £ millions |
Sales | Deferred income |
Committed sales |
Total remaining transaction price |
2021 | 2022 | 2023 and later |
|||||||||||||||||||||
Courseware |
||||||||||||||||||||||||||||
Products transferred at a point in time |
— | — | — | |||||||||||||||||||||||||
Products and services transferred over time |
||||||||||||||||||||||||||||
Assessments |
||||||||||||||||||||||||||||
Products transferred at a point in time |
— | — | — | |||||||||||||||||||||||||
Products and services transferred over time |
||||||||||||||||||||||||||||
Services |
||||||||||||||||||||||||||||
Products transferred at a point in time |
— | — | — | |||||||||||||||||||||||||
Products and services transferred over time – subscriptions |
— | |||||||||||||||||||||||||||
Products and services transferred over time – other ongoing performance obligations |
— | |||||||||||||||||||||||||||
Total |
||||||||||||||||||||||||||||
2019 |
||||||||||||||||||||||||||||
All figures in £ millions |
Sales |
Deferred income |
Committed sales |
Total remaining transaction price |
2020 |
2021 |
2022 and later |
|||||||||||||||||||||
Courseware |
||||||||||||||||||||||||||||
Products transferred at a point in time |
— |
— |
— |
|||||||||||||||||||||||||
Products and services transferred over time |
— |
|||||||||||||||||||||||||||
Assessments |
||||||||||||||||||||||||||||
Products transferred at a point in time |
— |
— |
— |
— |
— |
— |
||||||||||||||||||||||
Products and services transferred over time |
||||||||||||||||||||||||||||
Services 1 |
||||||||||||||||||||||||||||
Products transferred at a point in time |
— |
— |
— |
|||||||||||||||||||||||||
Products and services transferred over time – subscriptions |
— |
— |
— |
|||||||||||||||||||||||||
Products and services transferred over time – other ongoing performance obligations |
— |
|||||||||||||||||||||||||||
Total |
||||||||||||||||||||||||||||
All figures in £ millions |
2021 |
2020 | 2019 | |||||||||
By function: |
||||||||||||
Cost of goods sold |
||||||||||||
|
|
|
|
|
|
|||||||
Operating expenses |
||||||||||||
Distribution costs |
||||||||||||
Selling, marketing and product development costs |
||||||||||||
Administrative and other expenses |
||||||||||||
Restructuring costs |
— | |||||||||||
Other income |
( |
) |
( |
) | ( |
) | ||||||
|
|
|
|
|
|
|||||||
Total net operating expenses |
||||||||||||
Other net gains and losses |
( |
) |
( |
) | ( |
) | ||||||
|
|
|
|
|
|
|||||||
Total |
||||||||||||
|
|
|
|
|
|
All figures in £ millions |
2021 |
2020 |
2019 |
|||||||||
By nature: |
||||||||||||
Product costs |
||||||||||||
Employee costs |
||||||||||||
Impairment of non-current assets |
— | |||||||||||
Property and facilities |
||||||||||||
Technology and communications |
||||||||||||
Professional and outsourced services |
||||||||||||
General and administrative costs |
— |
— | ||||||||||
|
|
|
|
|
|
|||||||
Total restructuring – operating expenses |
||||||||||||
|
|
|
|
|
|
|||||||
Share of associate restructuring |
||||||||||||
|
|
|
|
|
|
|||||||
Total |
||||||||||||
|
|
|
|
|
|
All figures in £ millions |
Notes | 2021 |
2020 | 2019 | ||||||||||||
By nature: |
||||||||||||||||
Royalties expensed |
||||||||||||||||
Other product costs |
||||||||||||||||
Employee benefit expense |
5 | |||||||||||||||
Contract labour |
||||||||||||||||
Employee-related expense |
||||||||||||||||
Promotional costs |
||||||||||||||||
Depreciation and impairment of property, plant and equipment |
10 | |||||||||||||||
Amortisation and impairment of intangible assets – product development |
20 | |||||||||||||||
Amortisation and impairment of intangible assets – software |
11 | |||||||||||||||
Amortisation and impairment of intangible assets – other |
11 | |||||||||||||||
Property and facilities |
||||||||||||||||
Technology and communications |
||||||||||||||||
Professional and outsourced services |
||||||||||||||||
Other general and administrative costs |
||||||||||||||||
Costs capitalised |
( |
) |
( |
) | ( |
) | ||||||||||
Other net gains and losses |
( |
) |
( |
) | ( |
) | ||||||||||
Other income |
( |
) |
( |
) | ( |
) | ||||||||||
|
|
|
|
|
|
|||||||||||
Total |
||||||||||||||||
|
|
|
|
|
|
All figures in £ millions |
2021 |
2020 | 2019 | |||||||||
The audit of parent company and consolidated financial statements |
||||||||||||
The audit of the company’s subsidiaries |
||||||||||||
|
|
|
|
|
|
|||||||
Total audit fees |
||||||||||||
Audit-related and other assurance services |
— | — | ||||||||||
Other non-audit services |
— | — | ||||||||||
|
|
|
|
|
|
|||||||
Total other services |
— | — | ||||||||||
Total non-audit services |
— | — | ||||||||||
|
|
|
|
|
|
|||||||
Total |
||||||||||||
|
|
|
|
|
|
All figures in £ millions |
2021 |
2020 | 2019 | |||||||||
Group audit fees including fees for attestation under section 404 of the Sarbanes-Oxley Act |
||||||||||||
Non-audit fees |
— | — | ||||||||||
|
|
|
|
|
|
|||||||
Total |
||||||||||||
|
|
|
|
|
|
All figures in £ millions |
Notes | 2021 |
2020 | 2019 | ||||||||||||
Employee benefit expense |
||||||||||||||||
Wages and salaries (including termination costs) |
||||||||||||||||
Social security costs |
||||||||||||||||
Share-based payment costs |
26 | |||||||||||||||
Retirement benefits – defined contribution plans |
25 | |||||||||||||||
Retirement benefits – defined benefit plans |
25 | |||||||||||||||
Other post-retirement medical benefits |
25 | — |
— | ( |
) | |||||||||||
|
|
|
|
|
|
|||||||||||
Total |
|
|
||||||||||||||
|
|
|
|
|
|
Average number employed |
2021 |
2020 | 2019 | |||||||||||||
Employee numbers |
||||||||||||||||
UK |
||||||||||||||||
Other European countries |
||||||||||||||||
US |
||||||||||||||||
Canada |
||||||||||||||||
Asia Pacific |
||||||||||||||||
Other countries |
||||||||||||||||
|
|
|
|
|
|
|||||||||||
Total |
||||||||||||||||
|
|
|
|
|
|
All figures in £ millions |
Notes | 2021 |
2020 | 2019 | ||||||||||||
Interest payable on financial liabilities at amortised cost and associated derivatives |
( |
) |
( |
) | ( |
) | ||||||||||
Interest on lease liabilities |
( |
) |
( |
) | ( |
) | ||||||||||
Net foreign exchange losses |
( |
) | ( |
) | ||||||||||||
Derivatives not in a hedge relationship |
( |
) | ( |
) | ||||||||||||
|
|
|
|
|
|
|||||||||||
Finance costs |
( |
) |
( |
) | ( |
) | ||||||||||
|
|
|
|
|
|
|||||||||||
Interest receivable on financial assets at amortised cost |
||||||||||||||||
Interest on lease receivables |
||||||||||||||||
Net finance income in respect of retirement benefits |
25 | |||||||||||||||
Fair value remeasurement of disposal proceeds |
— | |||||||||||||||
Net foreign exchange gains |
— | — |
||||||||||||||
Derivatives not in a hedge relationship |
||||||||||||||||
|
|
|
|
|
|
|||||||||||
Finance income |
||||||||||||||||
|
|
|
|
|
|
|||||||||||
Net finance costs |
( |
) |
( |
) | ( |
) | ||||||||||
|
|
|
|
|
|
All figures in £ millions |
Notes | 2021 |
2020 | 2019 | ||||||||||||
Current tax |
||||||||||||||||
Charge in respect of current year |
( |
) |
( |
) | ( |
) | ||||||||||
Adjustments in respect of prior years |
( |
) |
||||||||||||||
|
|
|
|
|
|
|||||||||||
Total current tax charge |
( |
) |
( |
) | ( |
) | ||||||||||
|
|
|
|
|
|
|||||||||||
Deferred tax |
||||||||||||||||
In respect of temporary differences |
( |
) | ||||||||||||||
Other adjustments in respect of prior years |
( |
) | ||||||||||||||
|
|
|
|
|
|
|||||||||||
Total deferred tax credit/(charge) |
13 | ( |
) | |||||||||||||
|
|
|
|
|
|
|||||||||||
Total tax credit/(charge) |
( |
) | ||||||||||||||
|
|
|
|
|
|
All figures in £ millions |
2021 |
2020 | 2019 | |||||||||
Profit before tax |
||||||||||||
Tax calculated at UK rate (2021: |
( |
) |
( |
) | ( |
) | ||||||
Effect of overseas tax rates |
( |
) |
( |
) | ( |
) | ||||||
Effect of UK rate change |
( |
) | — | |||||||||
Joint venture and associate income reported net of tax |
||||||||||||
Intra-group financing benefit |
||||||||||||
Movement in provisions for tax uncertainties |
||||||||||||
Net expense not subject to tax |
( |
) |
( |
) | ( |
) | ||||||
Gains and losses on sale of businesses not subject to tax |
||||||||||||
Unrecognised tax losses |
( |
) | ( |
) | ||||||||
Benefit from changes in local tax law |
— | — | ||||||||||
Benefit from US accounting method changes |
— | — | ||||||||||
Adjustments in respect of prior years |
||||||||||||
|
|
|
|
|
|
|||||||
Total tax credit/(charge) |
( |
) | ||||||||||
|
|
|
|
|
|
|||||||
UK |
( |
) | ||||||||||
Overseas |
( |
) |
( |
) | ||||||||
|
|
|
|
|
|
|||||||
Total tax credit/(charge) |
( |
) | ||||||||||
|
|
|
|
|
|
|||||||
Tax rate reflected in earnings |
( |
)% |
% | ( |
)% | |||||||
|
|
|
|
|
|
All figures in £ millions |
2021 |
2020 |
2019 |
|||||||||
Net exchange differences on translation of foreign operations |
( |
) | ||||||||||
Fair value gain on other financial assets |
( |
) |
( |
) | ( |
) | ||||||
Remeasurement of retirement benefit obligations |
( |
) |
||||||||||
|
|
|
|
|
|
|||||||
( |
) |
( |
) | |||||||||
|
|
|
|
|
|
All figures in £ millions |
2021 |
2020 | 2019 | |||||||||
Earnings for the year |
||||||||||||
Non-controlling interest |
( |
) |
( |
) | ||||||||
|
|
|
|
|
|
|||||||
Earnings attributable to equity shareholders |
||||||||||||
|
|
|
|
|
|
|||||||
Weighted average number of shares (millions) |
||||||||||||
Effect of dilutive shares options (millions) |
||||||||||||
Weighted average number of shares (millions) for diluted earnings |
||||||||||||
Earnings per share (in pence per share) |
||||||||||||
Basic |
p |
p | p | |||||||||
Diluted |
p |
p | p | |||||||||
|
|
|
|
|
|
All figures in £ millions |
2021 |
2020 | 2019 | |||||||||
Final paid in respect of prior year p (2020: p; 2019: p) |
||||||||||||
Interim paid in respect of current year p (2020: p; 2019: p) |
||||||||||||
Right-of-use assets |
Owned assets | |||||||||||||||||||||||
All figures in £ millions |
Land and buildings |
Plant and equipment |
Land and buildings |
Plant and equipment |
Assets in the course of construction |
Total | ||||||||||||||||||
Cost |
||||||||||||||||||||||||
At 1 January 2020 |
||||||||||||||||||||||||
Exchange differences |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
Additions |
||||||||||||||||||||||||
Disposals and retirements |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
Reclassifications and transfers |
( |
) | ( |
) | ||||||||||||||||||||
Transfer to assets classified as held for sale |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
At 31 December 2020 |
||||||||||||||||||||||||
Exchange differences |
( |
) |
( |
) | ||||||||||||||||||||
Additions |
||||||||||||||||||||||||
Disposals and retirements |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||
Reclassifications and transfers |
( |
) |
||||||||||||||||||||||
Transfer to assets classified as held for sale |
( |
) |
( |
) | ||||||||||||||||||||
At 31 December 2021 |
||||||||||||||||||||||||
Right-of-use |
Owned assets | |||||||||||||||||||||||
All figures in £ millions |
Land and buildings |
Plant and equipment |
Land and buildings |
Plant and equipment |
Assets in the course of construction |
Total | ||||||||||||||||||
Depreciation and impairment |
||||||||||||||||||||||||
At 1 January 2020 |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Exchange differences |
||||||||||||||||||||||||
Charge for the year |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Disposals and retirements |
||||||||||||||||||||||||
Reclassifications and transfers |
( |
) | ||||||||||||||||||||||
Impairment of assets to be classified as held for sale |
( |
) | ( |
) | ||||||||||||||||||||
Transfer to assets classified as held for sale |
||||||||||||||||||||||||
At 31 December 2020 |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Exchange differences |
( |
) |
( |
) |
||||||||||||||||||||
Charge for the year |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||
Disposals and retirements |
||||||||||||||||||||||||
Reclassifications and transfers |
( |
) |
||||||||||||||||||||||
Impairment |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
Transfer to assets classified as held for sale |
||||||||||||||||||||||||
At 31 December 2021 |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||
Carrying amounts |
||||||||||||||||||||||||
At 1 January 2020 |
||||||||||||||||||||||||
At 31 December 2020 |
||||||||||||||||||||||||
At 31 December 2021 |
||||||||||||||||||||||||
All figures in £ millions |
Goodwill | Software | Acquired customer lists, contracts and relationships |
Acquired trademarks and brands |
Acquired publishing rights |
Other intangibles acquired |
Total | |||||||||||||||||||||
Cost |
||||||||||||||||||||||||||||
At 1 January 2020 |
||||||||||||||||||||||||||||
Exchange differences |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Additions – internal development |
— | — | — | — | — | |||||||||||||||||||||||
Additions – purchased |
— | — | — | — | — | |||||||||||||||||||||||
Disposals and retirements |
— | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||
Transfers |
— | — | — | — | — | |||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
At 31 December 2020 |
||||||||||||||||||||||||||||
Exchange differences |
( |
) |
( |
) |
||||||||||||||||||||||||
Additions – internal development |
— |
— |
— |
— |
— |
|||||||||||||||||||||||
Additions – purchased |
— |
— |
— |
— |
— |
|||||||||||||||||||||||
Disposals and retirements |
— |
( |
) |
( |
) |
( |
) |
( |
) | |||||||||||||||||||
Acquisition of subsidiary |
— |
— |
— |
— |
||||||||||||||||||||||||
Disposal of subsidiary |
— |
— |
( |
) |
( |
) |
— |
( |
) |
( |
) | |||||||||||||||||
Transfers |
— |
— |
— |
— |
— |
|||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
At 31 December 2021 |
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All figures in £ millions |
Goodwill | Software | Acquired customer lists, contracts and relationships |
Acquired trademarks and brands |
Acquired publishing rights |
Other intangibles acquired |
Total | |||||||||||||||||||||
Amortisation and impairment |
||||||||||||||||||||||||||||
At 1 January 2020 |
— | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||
Exchange differences |
— | |||||||||||||||||||||||||||
Charge for the year |
— | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||
Impairment charge |
— | — | ( |
) | — | — | ( |
) | ( |
) | ||||||||||||||||||
Disposals |
— | |||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
At 31 December 2020 |
— |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | |||||||||||||||
Exchange differences |
— |
( |
) |
( |
) |
( |
) |
( |
) | |||||||||||||||||||
Charge for the year |
— |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | |||||||||||||||||
Impairment charge |
— |
( |
) |
— |
— |
( |
) | |||||||||||||||||||||
Disposals and retirements |
— |
— |
— |
|||||||||||||||||||||||||
Disposal of subsidiary |
— |
— |
— |
|||||||||||||||||||||||||
Transfers |
— |
— |
— |
— |
— |
|||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
At 31 December 2021 |
— |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Carrying amounts |
||||||||||||||||||||||||||||
At 1 January 2020 |
||||||||||||||||||||||||||||
At 31 December 2020 |
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
At 31 December 2021 |
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2021 |
||||
Useful economic life |
||||
Class of intangible asset |
||||
Acquired customer lists, contracts and relationships |
||||
Acquired trademarks and brands |
||||
Acquired publishing rights |
||||
Other intangibles acquired |
2021 |
||||||||||||
All figures in £ millions |
One to five years |
Six to ten years |
Total |
|||||||||
Class of intangible asset |
||||||||||||
Acquired customer lists, contracts and relationships |
||||||||||||
Acquired trademarks and brands |
||||||||||||
Acquired publishing rights |
— |
|||||||||||
Other intangibles acquired |
2021 |
||||
All figures in £ millions |
Goodwill |
|||
Assessment & Qualifications |
||||
Virtual Learning |
||||
English Language Learning |
||||
Workforce Skills |
||||
Higher Education |
||||
Strategic Review (includes the separate CGUs of China, India, South Africa, Canada and Other Strategic Review) |
||||
Total |
||||
2020 | ||||
All figures in £ millions |
Goodwill | |||
North American Courseware |
— | |||
OPM |
||||
Virtual Schools |
||||
Assessments |
||||
International (includes the separate CGUs of Brazil, China, India and South Africa) |
||||
Total |
||||
Discount rate | Perpetuity growth rate |
|||||||
Assessment & Qualifications |
% |
% | ||||||
Virtual Learning |
% |
% | ||||||
English Language Learning |
% |
% | ||||||
Workforce Skills |
% |
% | ||||||
Higher Education |
% |
% | ||||||
Strategic Review |
% |
% |
All figures in £ millions |
2021 |
2020 | ||||||
Associates |
||||||||
Total |
||||||||
All figures in £ millions |
2021 |
2020 | ||||||
Associates |
||||||||
Total |
||||||||
All figures in £ millions |
2021 |
2020 | ||||||
Deferred income tax assets |
||||||||
Deferred income tax liabilities |
( |
) |
( |
) | ||||
Net deferred income tax asset/(liability) |
( |
) | ||||||
All figures in £ millions |
Trading losses |
Accruals and other provisions |
Retirement benefit obligations |
Deferred revenue |
Goodwill and intangibles |
Interest limitations |
Other | Total | ||||||||||||||||||||||||
Deferred income tax assets/ (liabilities) |
||||||||||||||||||||||||||||||||
At 1 January 2020 |
( |
) | ( |
) | ||||||||||||||||||||||||||||
Exchange differences |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||
Income statement (charge)/benefit |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
Tax benefit/(charge) in other comprehensive income |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||||||
At 31 December 2020 |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||||
Exchange differences |
— |
( |
) |
— |
— |
( |
) |
— |
( |
) | ||||||||||||||||||||||
Acquisition of subsidiaries |
— |
— |
— |
— |
— |
|||||||||||||||||||||||||||
Income statement benefit/(charge) |
( |
) |
||||||||||||||||||||||||||||||
Tax charge in other comprehensive income |
— |
— |
( |
) |
— |
— |
— |
( |
) |
( |
) | |||||||||||||||||||||
At 31 December 2021 |
( |
) |
( |
) |
||||||||||||||||||||||||||||
2021 |
2020 |
|||||||||||||||||||||||||||||||||||||||||||
Fair value |
Amortised cost |
Fair value |
Amortised cost |
|||||||||||||||||||||||||||||||||||||||||
All figures in £ millions |
Notes |
Fair value through other comprehensive income |
Fair value through profit and loss |
Fair value – hedging instrument |
Financial assets |
Total carrying value |
Fair value through other comprehensive income |
Fair value through profit and loss |
Fair value – hedging instrument |
Financial assets |
Total carrying value |
|||||||||||||||||||||||||||||||||
Investments in unlisted securities |
15 | — |
— |
— |
— | — | — | |||||||||||||||||||||||||||||||||||||
Cash and cash equivalents |
17 | — |
— |
— | — | |||||||||||||||||||||||||||||||||||||||
Derivative financial instruments |
16 | — |
— |
— | — | |||||||||||||||||||||||||||||||||||||||
Trade receivables |
22 | — |
— |
— |
— | — | — | |||||||||||||||||||||||||||||||||||||
Investment in finance lease receivable |
22 | — |
— |
— | — | |||||||||||||||||||||||||||||||||||||||
Other receivable |
— |
— |
— | — | — | |||||||||||||||||||||||||||||||||||||||
Total financial assets |
||||||||||||||||||||||||||||||||||||||||||||
2021 |
2020 |
|||||||||||||||||||||||||||||||||||||||||||
Fair value |
Amortised cost |
Fair value |
Amortised cost |
|||||||||||||||||||||||||||||||||||||||||
All figures in £ millions |
Notes |
Fair value through profit and loss |
Fair value – hedging instrument |
Other financial liabilities |
Total carrying value |
Total market value |
Fair value through profit and loss |
Fair value – hedging instrument |
Other financial liabilities |
Total carrying value |
Total market value |
|||||||||||||||||||||||||||||||||
Derivative financial instruments |
16 | ( |
) |
( |
) |
— |
( |
) |
( |
) |
( |
) | ( |
) | — | ( |
) | ( |
) | |||||||||||||||||||||||||
Trade payables |
24 | — |
— |
( |
) |
( |
) |
( |
) |
— | — | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||
Bank loans and overdrafts |
18 | — |
— |
— | — | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||
Other borrowings due within one year |
18 | — |
— |
( |
) |
( |
) |
( |
) |
— | — | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||
Borrowings due after more than one year |
18 | — |
— |
( |
) |
( |
) |
( |
) |
— | — | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||
Total financial liabilities |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
2021 |
2020 | |||||||||||||||
All figures in £ millions |
Other receivable |
Investments in unlisted securities |
Total |
Total | ||||||||||||
At beginning of year |
||||||||||||||||
Exchange differences |
( |
) | ||||||||||||||
Acquisition of investments and other receivable |
— |
|||||||||||||||
Disposal of investments and other payables |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||
Fair value movements |
||||||||||||||||
At end of year |
||||||||||||||||
All figures in £ millions |
2021 |
2020 | ||||||
At beginning of year |
||||||||
Exchange differences |
( |
) | ||||||
Acquisition of investments |
||||||||
Disposal of investments |
( |
) |
— | |||||
Fair value movements |
||||||||
At end of year |
||||||||
2021 |
2020 | |||||||||||||||||||||||
All figures in £ millions |
Gross notional amounts |
Assets |
Liabilities |
Gross notional amounts |
Assets | Liabilities | ||||||||||||||||||
Interest rate derivatives – in a fair value hedge relationship |
— |
— | ||||||||||||||||||||||
Interest rate derivatives – not in a hedge relationship |
— |
( |
) |
— | ( |
) | ||||||||||||||||||
Cross-currency rate derivatives – in a hedge relationship |
( |
) |
( |
) | ||||||||||||||||||||
FX derivatives – in a hedge relationship |
( |
) |
( |
) | ||||||||||||||||||||
FX derivatives – not in a hedge relationship |
— |
( |
) |
( |
) | |||||||||||||||||||
Total |
( |
) |
( |
) | ||||||||||||||||||||
Analysed as expiring: |
||||||||||||||||||||||||
In less than one year |
( |
) |
( |
) | ||||||||||||||||||||
Later than one year and not later than five years |
( |
) |
( |
) | ||||||||||||||||||||
Later than five years |
— |
( |
) |
— | ( |
) | ||||||||||||||||||
Total |
( |
) |
( |
) | ||||||||||||||||||||
• | Where interest rate and cross-currency interest rate swaps are used to convert fixed rate debt to floating and we expect to receive inflows equal to the fixed rate debt interest, these are classified as fair value hedges |
• | Where derivatives are used to create a future foreign currency liability to provide protection against currency movements affecting the valuation of an overseas investment, these are designated as a net investment hedge |
• | If the derivative and the underlying hedged exposure would normally be revalued through the income statement and valuation changes are expected to be perfectly or near perfectly equal and opposite, these will not be classified in a hedge relationship. |
2021 |
||||||||||||
All figures in £ millions |
Carrying amount of hedging instruments |
Change in fair value of hedging instrument used to determine hedge ineffectiveness |
Nominal amounts of hedging instruments |
|||||||||
Derivative financial instruments for interest rate risk |
( |
) |
||||||||||
Derivative financial instruments for currency risk |
( |
) |
||||||||||
2020 |
||||||||||||
All figures in £ millions |
Carrying amount of hedging instruments |
Change in fair value of hedging instrument used to determine hedge ineffectiveness |
Nominal amounts of hedging instruments |
|||||||||
Derivative financial instruments for interest rate risk |
— | |||||||||||
Derivative financial instruments for currency risk |
2021 |
||||||||||||||||||||
All figures in £ millions |
Carrying amount of hedged items |
Accumulated amount of fair value hedge adjustments on the hedged item included in the carrying amount |
Change in fair value of hedged item used to determine hedge ineffectiveness |
Hedge ineffectiveness |
Line item in profit or loss that includes hedge ineffectiveness |
|||||||||||||||
Interest rate risk |
||||||||||||||||||||
Financial liabilities – borrowings |
( |
) |
( |
) |
||||||||||||||||
Currency risk |
||||||||||||||||||||
Financial liabilities – borrowings |
( |
) |
n/a |
|||||||||||||||||
2020 |
||||||||||||||||||||
All figures in £ millions |
Carrying amount of hedged items |
Accumulated amount of fair value hedge adjustments on the hedged item included in the carrying amount |
Change in fair value of hedged item used to determine hedge ineffectiveness |
Hedge ineffectiveness |
Line item in profit or loss that includes hedge ineffectiveness |
|||||||||||||||
Interest rate risk |
||||||||||||||||||||
Financial liabilities – borrowings |
( |
) | ( |
) | ||||||||||||||||
Currency risk |
||||||||||||||||||||
Financial liabilities – borrowings |
( |
) | n/a | ( |
) |
2021 |
||||||||||||||||||||
All figures in £ millions |
Carrying amount of hedging instruments |
Change in value of hedging instrument used to determine hedge ineffectiveness |
Nominal amounts of hedging instruments |
Hedging gains/(losses) recognised in OCI |
Hedge ineffectiveness recognised in profit or loss |
|||||||||||||||
Derivative financial instruments |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||
Financial liabilities – borrowings |
( |
) |
( |
) |
2020 |
||||||||||||||||||||
All figures in £ millions |
Carrying amount of hedging instruments |
Change in value of hedging instrument used to determine hedge ineffectiveness |
Nominal amounts of hedging instruments |
Hedging gains/(losses) recognised in OCI |
Hedge ineffectiveness recognised in profit or loss |
|||||||||||||||
Derivative financial instruments |
( |
) | ( |
) | ||||||||||||||||
Financial liabilities – borrowings |
( |
) | ( |
) |
2021 |
2020 |
|||||||||||||||||||||||
All figures in £ millions |
Gross derivative assets |
Gross derivative liabilities |
Net derivative assets/ liabilities |
Gross derivative assets |
Gross derivative liabilities |
Net derivative assets/ liabilities |
||||||||||||||||||
Counterparties in an asset position |
( |
) |
( |
) | ||||||||||||||||||||
Counterparties in a liability position |
( |
) |
( |
) |
( |
) | ( |
) | ||||||||||||||||
Total as presented in the balance sheet |
( |
) |
( |
) |
( |
) | ||||||||||||||||||
All figures in £ millions |
2021 |
2020 |
||||||
Cash at bank and in hand |
||||||||
Short-term bank deposits |
||||||||
All figures in £ millions |
2021 |
2020 |
||||||
Cash and cash equivalents |
||||||||
Bank overdrafts |
— |
( |
) | |||||
All figures in £ millions |
2021 |
2020 |
||||||
Non-current |
||||||||
— |
||||||||
Lease liabilities (see note 35) |
||||||||
Current (due within one year or on demand) |
||||||||
Bank loans and overdrafts |
— |
|||||||
— |
||||||||
— | ||||||||
Lease liabilities (see note 35) |
||||||||
Total borrowings |
||||||||
All figures in £ millions |
2021 |
2020 |
||||||
Between one and two years |
||||||||
Between two and five years |
||||||||
Over five years |
||||||||
2021 |
2020 |
|||||||||||||||||||||||
All figures in £ millions |
Effective interest rate |
Carrying value |
Market value |
Effective interest rate |
Carrying value |
Market value |
||||||||||||||||||
Bank loans and overdrafts |
n/a |
— |
— |
n/a | ||||||||||||||||||||
1.875% euro notes 2021 |
n/a |
— |
— |
% | ||||||||||||||||||||
3.75% US dollar notes 2022 |
% |
% | ||||||||||||||||||||||
3.25% US dollar notes 2023 |
% |
% | ||||||||||||||||||||||
1.375% euro notes 2025 |
% |
% | ||||||||||||||||||||||
3.75% GBP notes 2030 |
% |
% | ||||||||||||||||||||||
All figures in £ millions |
2021 |
2020 |
||||||
US dollar |
||||||||
Sterling |
||||||||
Euro |
||||||||
Other |
||||||||
• | To maintain a strong balance sheet and a solid investment grade rating; |
• | To continue to invest in the business organically and through acquisitions; and |
• | To have a sustainable and progressive dividend policy. |
All figures in £ millions |
2021 |
2020 |
||||||
Cash and cash equivalents |
||||||||
Derivative financial instruments |
( |
) |
||||||
Bank loans and overdrafts |
— |
( |
) | |||||
Bonds |
( |
) |
( |
) | ||||
Investment in finance lease receivable |
||||||||
Lease liabilities |
( |
) |
( |
) | ||||
Net debt |
( |
) |
( |
) | ||||
2021 |
||||||||||||||||||||
All figures in £ millions |
Carrying value |
Impact of 1% increase in interest rates |
Impact of 1% decrease in interest rates |
Impact of 10% strengthening in sterling |
Impact of 10% weakening in sterling |
|||||||||||||||
Investments in unlisted securities |
— |
— |
( |
) |
||||||||||||||||
Other receivable |
— |
— |
( |
) |
||||||||||||||||
Cash and cash equivalents |
— |
— |
( |
) |
||||||||||||||||
Derivative financial instruments |
( |
) |
( |
) |
( |
) |
||||||||||||||
Bonds |
( |
) |
( |
) |
( |
) | ||||||||||||||
Other borrowings |
( |
) |
— |
— |
( |
) | ||||||||||||||
Investment in finance lease receivable |
— |
— |
( |
) |
||||||||||||||||
Other net financial assets |
— |
— |
( |
) |
||||||||||||||||
Total |
( |
) |
( |
) |
||||||||||||||||
2020 |
||||||||||||||||||||
All figures in £ millions |
Carrying value |
Impact of 1% increase in interest rates |
Impact of 1% decrease in interest rates |
Impact of 10% strengthening in sterling |
Impact of 10% weakening in sterling |
|||||||||||||||
Investments in unlisted securities |
— | — | ( |
) | ||||||||||||||||
Other receivable |
— | — | ( |
) | ||||||||||||||||
Cash and cash equivalents |
— | — | ( |
) | ||||||||||||||||
Derivative financial instruments |
( |
) | ||||||||||||||||||
Bonds |
( |
) | ( |
) | ( |
) | ||||||||||||||
Other borrowings |
( |
) | — | — | ( |
) | ||||||||||||||
Investment in finance lease receivable |
— | — | ( |
) | ||||||||||||||||
Other net financial assets |
— | — | ( |
) | ||||||||||||||||
Total |
( |
) | ( |
) | ( |
) | ||||||||||||||
Analysed by maturity |
Analysed by currency |
|||||||||||||||||||||||||||||||
All figures in £ millions |
Greater than one month and less than one year |
Later than one year but less than five years |
Five years or more |
Total |
USD |
GBP |
Other |
Total |
||||||||||||||||||||||||
At 31 December 2021 |
||||||||||||||||||||||||||||||||
Bonds |
||||||||||||||||||||||||||||||||
Rate derivatives – inflows |
( |
) |
( |
) | — |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | |||||||||||||||||
Rate derivatives – outflows |
||||||||||||||||||||||||||||||||
FX forwards – inflows |
( |
) | — |
— |
( |
) |
— |
( |
) |
— |
( |
) | ||||||||||||||||||||
FX forwards – outflows |
— |
— |
— |
|||||||||||||||||||||||||||||
Total |
||||||||||||||||||||||||||||||||
At 31 December 2020 |
||||||||||||||||||||||||||||||||
Bonds |
||||||||||||||||||||||||||||||||
Rate derivatives – inflows |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
Rate derivatives – outflows |
||||||||||||||||||||||||||||||||
FX forwards – inflows |
( |
) | — | — | ( |
) | — | ( |
) | — | ( |
) | ||||||||||||||||||||
FX forwards – outflows |
— | — | — | |||||||||||||||||||||||||||||
Total |
||||||||||||||||||||||||||||||||
All figures in £ millions |
2021 |
2020 |
||||||
Cost |
||||||||
At 1 January |
||||||||
Exchange differences |
— | ( |
) | |||||
Additions |
||||||||
Disposals and retirements |
( |
) |
( |
) | ||||
Disposal of subsidiary |
( |
) |
||||||
Transfers |
( |
) |
( |
) | ||||
At 31 December |
||||||||
Amortisation |
||||||||
At 1 January |
( |
) |
( |
) | ||||
Exchange differences |
( |
) |
||||||
Charge for the year |
( |
) |
( |
) | ||||
Impairment |
( |
) |
— | |||||
Disposals and retirements |
||||||||
Disposal of subsidiary |
— | |||||||
Transfers |
( |
) |
— | |||||
At 31 December |
( |
) |
( |
) | ||||
Carrying amounts at 31 December 2021 |
||||||||
All figures in £ millions |
2021 |
2020 |
||||||
Raw materials |
||||||||
Work in progress |
||||||||
Finished goods |
||||||||
Returns asset |
||||||||
All figures in £ millions |
2021 |
2020 |
||||||
Current |
||||||||
Trade receivables |
||||||||
Royalty advances |
||||||||
Prepayments |
||||||||
Investment in finance lease receivable |
||||||||
Accrued income |
||||||||
Other receivables |
||||||||
Non-current |
||||||||
Trade receivables |
||||||||
Royalty advances |
||||||||
Prepayments |
||||||||
Investment in finance lease receivable |
||||||||
Accrued income |
||||||||
Interest receivable |
— | |||||||
Other receivables |
||||||||
All figures in £ millions |
2021 |
2020 |
||||||
At beginning of year |
( |
) |
( |
) | ||||
Exchange differences |
— |
|||||||
Income statement movements |
( |
) |
( |
) | ||||
Utilised |
||||||||
Disposal of subsidiary |
— |
|||||||
At end of year |
( |
) |
( |
) | ||||
All figures in £ millions |
2021 |
2020 |
||||||
Within due date |
||||||||
Up to three months past due date |
||||||||
Three to six months past due date |
||||||||
Six to nine months past due date |
||||||||
Nine to 12 months past due date |
||||||||
More than 12 months past due date |
||||||||
|
|
|
|
|||||
Gross trade receivables |
||||||||
|
|
|
|
All figures in £ millions |
Property |
Disposals and closures |
Legal and other |
Total |
||||||||||||
At 1 January 2021 |
||||||||||||||||
Exchange differences |
— |
— |
||||||||||||||
Provisions made during the year |
||||||||||||||||
Provisions reversed during the year |
( |
) |
— |
( |
) |
( |
) | |||||||||
Provisions used during the year |
— |
— |
( |
) |
( |
) | ||||||||||
Disposal of subsidiary |
— |
( |
) |
— |
( |
) | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
At 31 December 2021 |
||||||||||||||||
|
|
|
|
|
|
|
|
Analysis of provisions: |
||||||||||||||||
2021 |
||||||||||||||||
All figures in £ millions |
Property |
Disposals and closures |
Legal and other |
Total |
||||||||||||
Current |
||||||||||||||||
Non-current |
— |
|||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|||||||||
2020 |
||||||||||||||||
Current |
||||||||||||||||
Non-current |
— | |||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
All figures in £ millions |
2021 |
2020 |
||||||
Trade payables |
||||||||
Sales return liability |
||||||||
Social security and other taxes |
||||||||
Accruals |
||||||||
Deferred income |
||||||||
Interest payable |
||||||||
Other liabilities |
||||||||
|
|
|
|
|||||
Less: non-current portion |
||||||||
Accruals |
— | |||||||
Deferred income |
||||||||
Other liabilities |
||||||||
|
|
|
|
|||||
|
|
|
|
|||||
Current portion |
||||||||
|
|
|
|
All figures in% |
Active |
Deferred |
Pensioners |
Total |
||||||||||||
Defined benefit |
— |
|||||||||||||||
Defined contribution |
||||||||||||||||
Total |
||||||||||||||||
2021 |
2020 |
2019 |
||||||||||||||||||||||||||||||||||
All figures in % |
UK Group plan |
Other plans |
PRMB |
UK Group plan |
Other plans |
PRMB |
UK Group plan |
Other plans |
PRMB |
|||||||||||||||||||||||||||
Inflation |
||||||||||||||||||||||||||||||||||||
Rate used to discount plan liabilities |
||||||||||||||||||||||||||||||||||||
Expected rate of increase in salaries |
||||||||||||||||||||||||||||||||||||
Expected rate of increase for pensions in payment and deferred pensions |
— |
— |
— | — | — | — | ||||||||||||||||||||||||||||||
Initial rate of increase in healthcare rate |
— |
— |
— | — | — | — | ||||||||||||||||||||||||||||||
Ultimate rate of increase in healthcare rate |
— |
— |
— | — | — | — |
UK |
US |
|||||||||||||||
All figures in years |
2021 |
2020 |
2021 |
2020 |
||||||||||||
Male |
||||||||||||||||
Female |
UK |
US |
|||||||||||||||
All figures in years |
2021 |
2020 |
2021 |
2020 |
||||||||||||
Male |
||||||||||||||||
Female |
2021 |
||||||||||||||||||||||||
All figures in £ millions |
UK Group plan |
Defined benefit other |
Sub-total |
Defined contribution |
PRMB |
Total |
||||||||||||||||||
Current service cost |
— |
|||||||||||||||||||||||
Past service cost |
— |
— |
— |
— |
— |
— |
||||||||||||||||||
Curtailments |
— |
— |
— |
— |
— |
— |
||||||||||||||||||
Administration expenses |
— |
— |
— |
|||||||||||||||||||||
Total operating expense |
— |
|||||||||||||||||||||||
Interest on plan assets |
( |
) |
( |
) |
( |
) |
— |
— |
( |
) | ||||||||||||||
Interest on plan liabilities |
— |
|||||||||||||||||||||||
Net finance (income)/expense |
( |
) |
( |
) |
— |
( |
) | |||||||||||||||||
Net income statement charge |
||||||||||||||||||||||||
2020 |
||||||||||||||||||||||||
All figures in £ millions |
UK Group plan |
Defined benefit other |
Sub-total |
Defined contribution |
PRMB |
Total |
||||||||||||||||||
Current service cost |
— | |||||||||||||||||||||||
Past service cost |
— | — | — | |||||||||||||||||||||
Curtailments |
— | ( |
) | ( |
) | — | — | ( |
) | |||||||||||||||
Administration expenses |
— | — | — | |||||||||||||||||||||
Total operating expense |
— | |||||||||||||||||||||||
Interest on plan assets |
( |
) | ( |
) | ( |
) | — | — | ( |
) | ||||||||||||||
Interest on plan liabilities |
— | |||||||||||||||||||||||
Net finance (income)/expense |
( |
) | ( |
) | — | ( |
) | |||||||||||||||||
Net income statement charge |
||||||||||||||||||||||||
2019 |
||||||||||||||||||||||||
All figures in £ millions |
UK Group plan |
Defined benefit other |
Sub-total |
Defined contribution |
PRMB |
Total |
||||||||||||||||||
Current service cost |
— |
|||||||||||||||||||||||
Past service cost |
— |
— |
— |
— |
— |
— |
||||||||||||||||||
Curtailments |
( |
) |
— |
( |
) |
— |
( |
) |
( |
) | ||||||||||||||
Administration expenses |
— |
— |
— |
|||||||||||||||||||||
Total operating expense |
( |
) | ||||||||||||||||||||||
Interest on plan assets |
( |
) |
( |
) |
( |
) |
— |
— |
( |
) | ||||||||||||||
Interest on plan liabilities |
— |
|||||||||||||||||||||||
Net finance (income)/expense |
( |
) |
( |
) |
— |
( |
) | |||||||||||||||||
Net income statement charge |
( |
) | ( |
) | ||||||||||||||||||||
2021 |
2020 |
|||||||||||||||||||||||||||||||
All figures in £ millions |
UK Group plan |
Other funded plans |
Other unfunded plans |
Total |
UK Group plan |
Other funded plans |
Other unfunded plans |
Total |
||||||||||||||||||||||||
Fair value of plan assets |
— |
— | ||||||||||||||||||||||||||||||
Present value of defined benefit obligation |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
Net pension asset/(liability) |
( |
) |
( |
) |
( |
) | ( |
) | ||||||||||||||||||||||||
Other post-retirement medical benefit obligation |
( |
) |
( |
) | ||||||||||||||||||||||||||||
Other pension accruals |
( |
) |
( |
) | ||||||||||||||||||||||||||||
Net retirement benefit asset |
||||||||||||||||||||||||||||||||
Analysed as: |
||||||||||||||||||||||||||||||||
Retirement benefit assets |
||||||||||||||||||||||||||||||||
Retirement benefit obligations |
( |
) |
( |
) |
All figures in £ millions |
2021 |
2020 |
2019 |
|||||||||
Amounts recognised for defined benefit plans |
( |
) | ( |
) | ||||||||
Amounts recognised for post-retirement medical benefit plans |
||||||||||||
Total recognised in year |
( |
) |
( |
) | ||||||||
2021 |
2020 |
|||||||||||||||||||||||
All figures in % |
UK Group plan |
Other funded plans |
Total |
UK Group plan |
Other funded plans |
Total |
||||||||||||||||||
Insurance |
— |
— | ||||||||||||||||||||||
Equities |
||||||||||||||||||||||||
Fixed interest securities |
||||||||||||||||||||||||
Property |
— |
— | ||||||||||||||||||||||
Pooled asset investment funds |
— |
— | ||||||||||||||||||||||
Other |
— |
— |
2021 |
2020 |
|||||||||||||||
All figures in % |
Quoted market price |
No quoted market price |
Quoted market price |
No quoted market price |
||||||||||||
Insurance |
||||||||||||||||
Equities |
||||||||||||||||
Fixed-interest securities |
||||||||||||||||
Property |
||||||||||||||||
Pooled asset investment funds |
||||||||||||||||
Other |
||||||||||||||||
Total |
||||||||||||||||
All figures in % |
2021 |
2020 |
||||||
Liquid – call <1 month |
||||||||
Less liquid – call 1–3 months |
— |
— | ||||||
Illiquid – call >3 months |
All figures in £ millions |
2021 |
2020 |
||||||||||||||||||||||
UK Group plan |
Other plans |
Total |
UK Group plan |
Other plans |
Total |
|||||||||||||||||||
Fair value of plan assets |
||||||||||||||||||||||||
Opening fair value of plan assets |
||||||||||||||||||||||||
Recognition of Money Purchase assets |
— |
— | — | — | ||||||||||||||||||||
Exchange differences |
— |
— | ( |
) | ( |
) | ||||||||||||||||||
Interest on plan assets |
||||||||||||||||||||||||
Return on plan assets excluding interest |
||||||||||||||||||||||||
Contributions by employer |
||||||||||||||||||||||||
Benefits paid |
( |
) |
( |
) |
( |
) |
( |
) | ( |
) | ( |
) | ||||||||||||
Contributions by employees |
— | — | — | |||||||||||||||||||||
Closing fair value of plan assets |
||||||||||||||||||||||||
Present value of defined benefit obligation |
||||||||||||||||||||||||
Opening defined benefit obligation |
( |
) |
( |
) |
( |
) |
( |
) | ( |
) | ( |
) | ||||||||||||
Recognition of Money Purchase liabilities |
( |
) |
— |
( |
) |
— | — | — | ||||||||||||||||
Exchange differences |
( |
) |
( |
) |
— | |||||||||||||||||||
Current service cost |
( |
) |
( |
) |
( |
) |
( |
) | ( |
) | ( |
) | ||||||||||||
Past service cost |
— |
— |
— |
( |
) | ( |
) | |||||||||||||||||
Curtailments |
— |
— |
— |
— | ||||||||||||||||||||
Administration expenses |
( |
) |
( |
) |
( |
) | ( |
) | ||||||||||||||||
Interest on plan liabilities |
( |
) |
( |
) |
( |
) |
( |
) | ( |
) | ( |
) | ||||||||||||
Actuarial (losses)/gains – experience |
( |
) |
( |
) |
( |
) | ( |
) | ( |
) | ||||||||||||||
Actuarial (losses)/gains – demographic |
( |
) |
( |
) |
||||||||||||||||||||
Actuarial gains/(losses) – financial |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
Contributions by employee |
( |
) |
( |
) |
||||||||||||||||||||
Benefits paid |
||||||||||||||||||||||||
Closing defined benefit obligation |
( |
) |
( |
) |
( |
) |
( |
) | ( |
) | ( |
) | ||||||||||||
All figures in £ millions |
2021 |
2020 |
||||||
Opening defined benefit obligation |
( |
) |
( |
) | ||||
Exchange differences |
( |
) |
||||||
Interest on plan liabilities |
( |
) |
( |
) | ||||
Actuarial gains – experience |
||||||||
Actuarial gains – demographic |
||||||||
Actuarial gains/(losses) – financial |
( |
) | ||||||
Benefits paid |
||||||||
Closing defined benefit obligation |
( |
) |
( |
) | ||||
2021 |
||||||||
All figures in £ millions |
increase |
decrease |
||||||
Effect: |
||||||||
(Decrease)/increase in defined benefit obligation – UK Group plan |
( |
) |
||||||
(Decrease)/increase in defined benefit obligation – US plan |
( |
) |
||||||
2021 |
||||||||
All figures in £ millions |
increase |
decrease |
||||||
Effect: |
||||||||
Increase/(decrease) in defined benefit obligation – UK Group plan |
( |
) | ||||||
Increase/(decrease) in defined benefit obligation – US plan |
( |
) | ||||||
2021 |
||||||||
All figures in £ millions |
increase |
decrease |
||||||
Effect: |
||||||||
Increase/(decrease) in defined benefit obligation – UK Group plan |
( |
) | ||||||
Increase/(decrease) in defined benefit obligation – US plan |
— |
— |
||||||
All figures in £ millions |
2021 |
2020 |
2019 |
|||||||||||||
Pearson plans |
2021 |
2020 |
|||||||||||||||
Number of shares 000s |
Weighted average fair value £ |
Number of shares 000s |
Weighted average fair value £ |
|||||||||||||
Long-Term Incentive Plan |
||||||||||||||||
Management Incentive Plan |
Number of shares 000s |
Share capital £m |
Share premium £m |
||||||||||
At 1 January 2020 |
||||||||||||
Issue of ordinary shares – share option schemes |
— | |||||||||||
Purchase of own shares |
( |
) | ( |
) | — | |||||||
At 31 December 2020 |
||||||||||||
Issue of ordinary shares – share option schemes |
||||||||||||
Purchase of own shares |
— |
— |
— |
|||||||||
At 31 December 2021 |
||||||||||||
Number of shares 000s |
£m |
|||||||
At 1 January 2020 |
||||||||
Purchase of treasury shares |
||||||||
Release of treasury shares |
( |
) | ( |
) | ||||
At 31 December 2020 |
||||||||
Purchase of treasury shares |
||||||||
Newly issued treasury shares |
||||||||
Release of treasury shares |
( |
) |
( |
) | ||||
At 31 December 2021 |
||||||||
2021 |
||||||||||||||||||||||||
Attributable to equity holders of the company |
Non- controlling interest |
Total |
||||||||||||||||||||||
All figures in £ millions |
Fair value reserve |
Translation reserve |
Retained earnings |
Total |
||||||||||||||||||||
Items that may be reclassified to the income statement |
||||||||||||||||||||||||
Net exchange differences on translation of foreign operations – Group |
— |
( |
) |
— |
( |
) |
— |
( |
) | |||||||||||||||
Currency translation adjustment disposed |
— |
— |
— |
|||||||||||||||||||||
Attributable tax |
— |
— |
— |
|||||||||||||||||||||
Items that are not reclassified to the income statement |
||||||||||||||||||||||||
Fair value gain on other financial assets |
— |
— |
— |
|||||||||||||||||||||
Attributable tax |
— |
— |
( |
) |
( |
) |
— |
( |
) | |||||||||||||||
Remeasurement of retirement benefit obligations - Group |
— |
— |
— |
|||||||||||||||||||||
Attributable tax |
— |
— |
( |
) |
( |
) |
— |
( |
) | |||||||||||||||
Other comprehensive income/(expense) for the year |
( |
) |
— |
|||||||||||||||||||||
2020 |
||||||||||||||||||||||||
Attributable to equity holders of the company |
Non- controlling interest |
Total |
||||||||||||||||||||||
All figures in £ millions |
Fair value reserve |
Translation reserve |
Retained earnings |
Total |
||||||||||||||||||||
Items that may be reclassified to the income statement |
||||||||||||||||||||||||
Net exchange differences on translation of foreign operations – Group |
— | ( |
) | — | ( |
) | — | ( |
) | |||||||||||||||
Currency translation adjustment disposed |
— | ( |
) | — | ( |
) | — | ( |
) | |||||||||||||||
Attributable tax |
— | — | ( |
) | ( |
) | — | ( |
) | |||||||||||||||
Items that are not reclassified to the income statement |
||||||||||||||||||||||||
Fair value gain on other financial assets |
— | — | — | |||||||||||||||||||||
Attributable tax |
— | — | ( |
) | ( |
) | — | ( |
) | |||||||||||||||
Remeasurement of retirement benefit obligations - Group |
— | — | ( |
) | ( |
) | — | ( |
) | |||||||||||||||
Attributable tax |
— | — | — | |||||||||||||||||||||
Other comprehensive income/(expense) for the year |
( |
) | ( |
) | ( |
) | — | ( |
) | |||||||||||||||
2019 |
||||||||||||||||||||||||
Attributable to equity holders of the company |
Non- controlling interest |
Total |
||||||||||||||||||||||
All figures in £ millions |
Fair value reserve |
Translation reserve |
Retained earnings |
Total |
||||||||||||||||||||
Items that may be reclassified to the income statement |
||||||||||||||||||||||||
Net exchange differences on translation of foreign operations – Group |
— | ( |
) | — | ( |
) | — | ( |
) | |||||||||||||||
Net exchange differences on translation of foreign operations – associates |
— | ( |
) | — | ( |
) | — | ( |
) | |||||||||||||||
Currency translation adjustment disposed |
— | — | — | |||||||||||||||||||||
Attributable tax |
— | — | — | |||||||||||||||||||||
Items that are not reclassified to the income statement |
||||||||||||||||||||||||
Fair value gain on other financial assets |
— | — | — | |||||||||||||||||||||
Attributable tax |
— | — | ( |
) | ( |
) | — | ( |
) | |||||||||||||||
Remeasurement of retirement benefit obligations – Group |
— | — | ( |
) | ( |
) | — | ( |
) | |||||||||||||||
Remeasurement of retirement benefit obligations – associates |
— | — | ( |
) | ( |
) | — | ( |
) | |||||||||||||||
Attributable tax |
— | — | — | |||||||||||||||||||||
Other comprehensive (expense)/income for the year |
( |
) | ( |
) | ( |
) | — | ( |
) | |||||||||||||||
All figures in £ millions |
2021 Faethm |
2021 Other |
2021 Total |
2020 Total |
2019 Total |
|||||||||||||||
Intangible assets |
— | |||||||||||||||||||
Deferred tax asset |
— |
— | — | |||||||||||||||||
Trade and other receivables |
— | |||||||||||||||||||
Cash |
— |
— | — | |||||||||||||||||
Trade and other liabilities |
( |
) |
( |
) |
( |
) |
— | ( |
) | |||||||||||
Deferred tax liabilities |
( |
) |
— |
( |
) |
— | — | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Net assets acquired |
— | |||||||||||||||||||
Goodwill |
— | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total |
— | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Satisfied by: |
||||||||||||||||||||
Cash consideration |
— | |||||||||||||||||||
Contingent consideration |
— | — | ||||||||||||||||||
Fair value of existing investment |
— |
— | — | |||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total consideration |
— | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
All figures in £ millions |
2021 Faethm |
2021 Other |
2021 Total |
2020 Total |
2019 Total |
|||||||||||||||
Cash flow on acquisitions |
||||||||||||||||||||
Cash – current year acquisitions |
( |
) |
( |
) |
( |
) |
— | ( |
) | |||||||||||
Cash and cash equivalents acquired |
— |
— | — | |||||||||||||||||
Deferred payments for prior year acquisitions and other items |
— |
( |
) |
( |
) |
( |
) | ( |
) | |||||||||||
Acquisition costs paid |
( |
) |
— |
( |
) |
— | — | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Net cash outflow |
( |
) |
( |
) |
( |
) |
( |
) | ( |
) | ||||||||||
|
|
|
|
|
|
|
|
|
|
All figures in £ millions |
Notes |
2021 |
2020 |
2019 |
||||||||||||
Disposal of subsidiaries and associates |
||||||||||||||||
Intangible assets |
( |
) |
— |
( |
) | |||||||||||
Property, plant and equipment |
( |
) |
— | — | ||||||||||||
Investments in joint ventures and associates |
— |
( |
) | — | ||||||||||||
Intangible assets – product development |
( |
) |
— | ( |
) | |||||||||||
Inventories |
( |
) |
— | ( |
) | |||||||||||
Trade and other receivables |
( |
) |
— | ( |
) | |||||||||||
Cash and cash equivalents (excluding overdrafts) |
( |
) |
— | ( |
) | |||||||||||
Net deferred income tax assets |
— |
— |
( |
) | ||||||||||||
Provisions for other liabilities and charges |
— | — | ||||||||||||||
Trade and other liabilities |
— | |||||||||||||||
Financial liabilities – borrowings |
— | — |
||||||||||||||
Cumulative currency translation adjustment |
29 | ( |
) |
( |
) | |||||||||||
|
|
|
|
|
|
|||||||||||
Net assets disposed |
( |
) |
( |
) | ( |
) | ||||||||||
Cash proceeds |
|
|||||||||||||||
Deferred proceeds |
— |
— |
||||||||||||||
Costs of disposal |
( |
) |
( |
) | ||||||||||||
|
|
|
|
|
|
|||||||||||
Gain on disposal |
||||||||||||||||
|
|
|
|
|
|
All figures in £ millions |
2021 |
2020 |
2019 |
|||||||||||||
Cash flow from disposals |
||||||||||||||||
Proceeds – current year disposals |
||||||||||||||||
Proceeds – prior year disposals |
— | |||||||||||||||
Cash and cash equivalents disposed |
( |
) |
— | ( |
) | |||||||||||
Costs and other disposal liabilities paid |
( |
) |
( |
) | ( |
) | ||||||||||
Net cash inflow |
( |
) | ||||||||||||||
Analysed as: |
||||||||||||||||
Cash inflow from sale of subsidiaries |
( |
) | ||||||||||||||
Cash inflow from disposal of joint ventures and associates |
— |
— |
2021 |
2020 |
|||||||
All figures in £ millions |
Total |
Total |
||||||
Non-current assets |
||||||||
Property, plant and equipment |
||||||||
Current assets |
||||||||
Trade and other receivables |
— |
|||||||
Cash and cash equivalents |
— |
|||||||
— |
||||||||
Assets classified as held for sale |
||||||||
Non-current liabilities |
||||||||
Financial liabilities – borrowings |
— |
( |
) | |||||
— |
( |
) | ||||||
Current liabilities |
||||||||
Trade and other liabilities |
— |
( |
) | |||||
Financial liabilities – borrowings |
— |
( |
) | |||||
— |
( |
) | ||||||
Liabilities classified as held for sale |
— |
( |
) | |||||
Net assets/(liabilities) classified as held for sale |
( |
) | ||||||
All figures in £ millions |
Notes |
2021 |
2020 |
2019 |
||||||||||||
Profit |
||||||||||||||||
Adjustments for: |
||||||||||||||||
Income tax |
( |
) |
( |
) | ||||||||||||
Depreciation and impairment of property, plant and equipment |
10 |
|||||||||||||||
Amortisation and impairment of acquired intangibles and goodwill |
11 |
|||||||||||||||
Amortisation and impairment of software |
11 | |||||||||||||||
Net finance costs |
6 | |||||||||||||||
Share of results of joint ventures and associates |
12 | ( |
) |
( |
) | ( |
) | |||||||||
Profit on disposal of subsidiaries, associates, investments and fixed assets |
( |
) |
( |
) | ( |
) | ||||||||||
Other net gains and losses |
— | |||||||||||||||
Net profit on disposal of right-of-use |
— |
( |
) | ( |
) | |||||||||||
Net foreign exchange adjustment from transactions |
( |
) | ( |
) | ||||||||||||
Investment income |
— |
— | ( |
) | ||||||||||||
Share-based payment costs |
26 | |||||||||||||||
Product development assets |
( |
) |
( |
) | ( |
) | ||||||||||
Inventories |
( |
) | ||||||||||||||
Trade and other receivables |
( |
) |
( |
) | ||||||||||||
Trade and other liabilities |
( |
) | ( |
) | ||||||||||||
Retirement benefit obligations |
( |
) | ||||||||||||||
Provisions for other liabilities and charges |
( |
) | ||||||||||||||
Net cash generated from operations |
||||||||||||||||
All figures in £ millions |
2021 |
2020 |
2019 |
|||||||||
Net book amount |
||||||||||||
Loss on sale of property, plant and equipment |
( |
) |
( |
) | ( |
) | ||||||
|
|
|
|
|
|
|||||||
Proceeds from sale of property, plant and equipment |
||||||||||||
|
|
|
|
|
|
All figures in £ millions |
2020 |
New leases/ disposal of leases |
Transfer from non-current to current |
Financing cash flows |
Foreign exchange movements |
Fair value and other movements |
2021 |
|||||||||||||||||||||
Financial liabilities |
||||||||||||||||||||||||||||
Non-current borrowings |
( |
) |
( |
) |
— |
( |
) |
|||||||||||||||||||||
Current borrowings |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Total |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All figures in £ millions |
2019 |
New leases/ disposal of leases |
Transfer from non-current to current |
Financing cash flows |
Foreign exchange movements |
Fair value and other movements |
2020 |
|||||||||||||||||||||
Financial liabilities |
||||||||||||||||||||||||||||
Non-current borrowings |
( |
) | ( |
) | ||||||||||||||||||||||||
Current borrowings |
( |
) | ( |
) | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Total |
( |
) | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All figures in £ millions |
2018 |
IFRS 16 Transition |
New leases/ disposal of leases |
Transfer from non-current to current |
Financing cash flows |
Foreign exchange movements |
Fair value and other movements |
2019 |
||||||||||||||||||||||||
Financial liabilities |
||||||||||||||||||||||||||||||||
Non-current borrowings |
( |
) | ( |
) | ||||||||||||||||||||||||||||
Current borrowings |
— | ( |
) | — | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Total |
( |
) | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All figures in £ millions |
Note |
2021 |
2020 |
2019 |
||||||||||||
Interest on lease liabilities |
( |
) |
( |
) | ( |
) | ||||||||||
Expenses relating to short-term leases |
— |
( |
) | ( |
) | |||||||||||
Depreciation of right-of-use |
10 | ( |
) |
( |
) | ( |
) | |||||||||
Impairment of right-of-use |
10 | ( |
) |
( |
) | — |
All figures in £ millions |
2021 |
2020 |
||||||
Less than one year |
||||||||
One to five years |
||||||||
More than five years |
||||||||
|
|
|
|
|||||
Total undiscounted lease liabilities |
||||||||
|
|
|
|
|||||
Lease liabilities included in the balance sheet |
||||||||
|
|
|
|
|||||
Analysed as: |
||||||||
Current |
||||||||
Non-current |
All figures in £ millions |
2021 |
2020 |
2019 |
|||||||||
Total cash outflow for leases as a lessee |
All figures in £ millions |
2021 |
2020 |
2019 |
|||||||||
Interest on lease receivables |
||||||||||||
Income from subleasing right-of-use |
All figures in £ millions |
2021 |
2020 |
2019 |
|||||||||
Total cash inflow for leases as a lessor |
All figures in £ millions |
Operating leases |
Finance leases |
2021 Total |
2020 Total |
||||||||||||
Less than one year |
||||||||||||||||
One to two years |
— |
|||||||||||||||
Two to three years |
||||||||||||||||
Three to four years |
||||||||||||||||
Four to five years |
||||||||||||||||
More than five years |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total undiscounted lease payments receivable |
||||||||||||||||
Unearned finance income |
( |
) |
||||||||||||||
|
|
|||||||||||||||
Net investment in finance lease receivable |
||||||||||||||||
|
|
All figures in £ millions |
2021 |
2020 |
||||||
Short-term employee benefits |
||||||||
Retirement benefits |
||||||||
Share-based payment costs |
||||||||
|
|
|
|
|||||
Total |
||||||||
|
|
|
|
Pearson plc |
/s/ Sally Johnson |
Sally Johnson |
Chief Financial Officer |